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HIV-1 primarily utilizes the CCR5 receptor as a co-receptor, but over time, 
viruses can evolve to use the CXCR4 protein. Changes in the viral envelope V3 loop 
mediate this switch. The emergence of CXCR4-utilizing viruses has been presumed to 
occur as a consequence of decreased humoral immunity. We show that exclusively 
CXCR4-using (X4) viruses contain a 2 to 3 amino acid insertion in the V3 loop. 
Structural modeling revealed that this insertion caused a protrusion in the V3 loop, which 
impacts CCR5 receptor interaction. These genotypic and structural motifs affected 
neutralization susceptibility because X4, as compared to co-circulating CCR5-utilizing 
(R5) viruses, were less neutralization sensitive to autologous contemporaneous and 
heterologous plasma. Individuals with co-circulating X4 and R5, as compared to those 
with only R5, viruses had similar neutralization breadth and potency indicating that the 
emergence of X4 viruses is not associated with decreased humoral immunity. These 
results suggest that X4 viruses are neutralization escape variants and arise due to humoral 
selective pressure. This work has implications for future antibody-based therapeutics.  
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Along with providing a framework for developing an HIV-1 vaccine, broadly 
neutralizing antibodies (bnAbs) are also being investigated as a potential therapeutic. 
BnAbs target a limited number of conserved HIV-1 envelope structures, including 
glycans in and around the V1/V2 and V3 domains. Along with the V3 loop, changes in 
V1/V2 are also known to impact co-receptor usage. We show that viruses that exclusively 
use the CXCR4 co-receptor, as compared to variants that only utilize CCR5, were less 
neutralization sensitive to V1/V2 and V3 directed bnAbs. In contrast, R5 and X4 viruses 
did not demonstrate neutralization differences to bnAbs that target non-V1/V2 and V3 
envelope regions, such as the CD4 binding site and the membrane proximal external 
region. Structural modeling revealed that the predicted orientation of the V1/V2 loop 
among diverse HIV-1 variants predicts susceptibility to V3 loop directed bnAbs. In 
aggregate, our results suggest that viruses with different co-receptor usage have differing 
bnAb susceptibility. Furthermore, structural modeling may be used as a tool to predict 
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CHAPTER ONE: INTRODUCTION 
HIV/AIDS 
 History and epidemiology 
 Acquired immune deficiency syndrome (AIDS) was first recognized within the 
United States in 1981 after the diagnosis of atypical infections in men who have sex with 
men (MSM) in San Francisco, California and New York, New York. Previously healthy 
young men were diagnosed with Pneumocystis carinii pneumonia (PCP). More cases of 
PCP and other opportunistic infections, including Kaposi’s sarcoma were reported in the 
following months (Centers for Disease, 1981; Centers for Disease, 1982a; Jaffe et al., 
1983; De Cock et al., 2012). Heterosexual transmission, as well as mother to child 
transmission, were documented shortly after (Centers for Disease, 1982c; Centers for 
Disease, 1983). While the causative agent had not yet been identified, it became evident 
that transmission occurred through blood as hemophiliacs and injection drug users 
became sick with the same immunodeficiency illness (Centers for Disease, 1982d; 
Centers for Disease, 1982b). Two years after the initial report, human immunodeficiency 
virus type 1(HIV-1), was identified and isolated by two separate labs. Dr. Françoise 
Barré-Sinoussi at the Pasteur Institute in France and Dr. Robert Gallo at the US National 
Cancer Institute both published reports on Lymphadenopathy Associated Virus and T-
Cell Leukemia Virus, respectively, in the same journal (Barre-Sinoussi et al., 1983; Gallo 
et al., 1983). In 1984, Dr. Gallo also developed a diagnostic blood test to identify HIV 
which the US Food and Drug Administration licensed in 1985. That same year at least 




 The 1980’s and early 1990’s were plagued by a misconception of what HIV/AIDS 
was and where it originated from. People would often refer to it as the 4-H disease for: 
homosexuals, hemophiliacs, heroin addicts, and Haitians. Cases of Haitians entering the 
United States with AIDS symptoms and then, cases described in Haiti were among the 
first reports of HIV/AIDS outside the United States (Pape et al., 1983; De Cock et al., 
2012). Through molecular epidemiologic studies, it is now understood that HIV-1 was 
introduced into the human population in the early twentieth century through a 
transmission event with chimpanzees in Africa. The earliest blood sample found to 
contain HIV is from 1959 from a man living in Kinahasa in the Democratic Republic of 
Congo (Avert; Faria et al., 2014). By the 1990’s, only several years after HIV/AIDS was 
recognized, more than 20 million people were estimated to be living with HIV/AIDS. 
Sub-Saharan Africa represented a vast majority of those infected and to this day is 
disproportionately represented in the global HIV epidemic. (De Cock et al., 2012).  
HIV-1 has since evolved into one of the greatest challenges affecting global 
health. As of 2016, approximately 36.7 million people are living with HIV worldwide. 
More than 70 million people have been infected with the virus and about 35 million 
people have died of HIV (World Health Organization). While many advances have been 
made in treatment, after over 30 years of research, there still remains no cure or vaccine. 
Therefore, public health approaches have been established through the years to reduce the 





Transmission, disease progression, and AIDS 
HIV is transmitted by exposure of bodily fluids, such as blood, semen, rectal 
fluids, and vaginal fluids, from an infected individual to a mucosal surface. More than 
80% of adult infections are caused by this route. The remaining 20% are caused by 
percutaneous or intravenous exposure, such as injection drug use (Cohen et al., 2011). 
Mother to child transmission during or at the time of pregnancy, labor, delivery or breast-
feeding account for the majority of new infant infections (World Health Organization). 
Despite the various routes of transmission, once infected, the course of disease is similar 
and follows an orderly pattern. Following initial exposure and infection, 40-90% of 
infected individuals experience symptoms of acute viral syndrome which may include, 
but are not limited to, fever, fatigue, headache, myalgia, weight loss, depression and oral 
or genital ulcers (Kahn and Walker, 1998). During this first 7-21 days, virus is not 
detected in plasma, and is referred to as the eclipse phase (Cohen et al., 2011). Early 
dissemination events occur during this phase. The first target cell of the virus is tissue 
dendritic cells found in the lamina propia. Fusion of dendritic cells and CD4+ T 
lymphocytes lead to dissemination of virus from the mucosa to regional lymph nodes 
(LN) by day two after exposure and infection. In the LN, infection is spread to activated 
CD4+ T cells. By day three, virus infected cells leave the LN and travel in the 
bloodstream causing widespread dissemination to the brain, spleen, gut-associated 
lymphoid tissue (GALT), and lymph nodes. Virus can be detected by PCR once HIV-1 





 The remainder of the acute stage is characterized by a rapid increase in HIV-1 
viral load until it reaches a peak, often in excess of 106 copies of RNA molecules/mL, 
before it plateaus to a steady-state level, referred to a viral set point (Kahn and Walker, 
1998). CD4+T cells have an inverse relationship to viral load. After HIV-1 
dissemination, massive CD4+ T cell depletion occurs as a result of both direct infection 
and indirect Fas/Fas ligand-mediated apoptosis of uninfected cells. A major site of CD4+ 
T cell depletion is the GALT. The physiological conditions in this tissue make it a highly 
susceptible target for HIV-1 infection. HIV-1 infects primarily CCR5+ CD4+ memory T 
cells. A majority of gastrointestinal (GI) mucosal CD4+ T cells are activated memory 
cells due to constant exposure to food and microbial antigens. In addition, the GI 
environment is maintained in a state of inflammation with a high percentage of 
proinflammatory, HIV-1 stimulatory cytokines expressed regularly. Together, these 
factors enable major destruction of GALT resident CD4+ T cells. Although CD4+T cells 
are reconstituted as equilibrium is reached between viremia and CD4+ T cells, GALT 
CD4+ T cells do not rebound (McMichael et al., 2010; Fevrier et al., 2011).  
Once chronic HIV-1 infection is established, the course of disease and 
progression depends primarily on host genetic and immunological factors (Barre-Sinoussi 
et al., 2013; Perreau et al., 2013). Virological factors, such as virus turn over and 
diversity, can also play a role in disease progression, however (Liu et al., 1997; Perreau et 
al., 2013). AIDS is reached in the late stage of infection when CD4+T cells are below 




opportunistic infections and have a poor prognosis (Center for Disease Control and 
Prevention).  
Subtypes 
HIV originated from multiple zoonotic transmission events of simian 
immunodeficiency virus (SIV) between non-human primates and humans (Faria et al., 
2014). These transmission events resulted in multiple HIV lineages: HIV-1 and HIV type 
2 (HIV-2). Each lineage contains numerous groups. HIV-1 is composed of groups M, N, 
O, and P, while HIV-2 consists of groups A-H (Hemelaar, 2012; Faria et al., 2014). HIV-
1 group M is responsible for the global HIV pandemic. Within group M, nine subtypes, 
A-D, F-H, J and K, exist and the prevalence of the subtypes varies in different parts of the 
world. Subtypes can differ by around 35% in the HIV-1 envelope gene (Lynch et al., 
2009). Multiple recombination events have also given rise to several circulating 
recombinant forms (CRFs). This group includes recombination’s between two or more 
subtypes. Around 89 CRFs have been documented to date (Hemelaar, 2012).  
Subtype C is responsible for the majority of HIV-1 infections worldwide. It 
accounts for nearly 50% of all infections and is highly prevalent in Southern Africa and 
India. Subtype B, which accounts for 12% of global infections, is dominant in North and 
South America, western Europe, Australia, and New Zealand. Subtype A is prevalent in 
central and eastern Africa, as well as eastern Europe. Together, subtypes A, B, and C 





HIV-1 binds the CD4 receptor for attachment to a host cell. In order for the virus 
to enter host cells, HIV must also bind a co-receptor. Two chemokine cell membrane 
bound proteins, CCR5 and CXCR4, are capable of being used as a co-receptor (Deng et 
al., 1996; Dragic et al., 1996; Feng et al., 1996). Viruses that exclusively use the CCR5 
receptor are termed R5 viruses (also referred to as non-syncytium-inducing) while those 
that only utilize the CXCR4 receptor are classified as X4 viruses (or syncytium-
inducing). Variants that can use either chemokine are known as R5X4 or dual-tropic. 
Individuals harboring a mixture of R5 and CXCR4-using viruses have a dual mixed 
(DM) population.  
The viral envelope glycoprotein (Env) mediates binding to host cells. The Env 
gene codes for one protein, gp160, which is cleaved into two proteins, gp120 and gp41, 
by the host cell protease, furin (Decroly et al., 1994). The viral spike is composed of a 
heterotrimer of gp120, which is noncovalently bound to three molecules of gp41, which 
anchors the structure to the viral membrane. Gp120 contains five variable loops (V1-V5) 
interspersed between five constant regions (C1-C5). Despite the nomenclature, the 
variable regions contain several regions that are well conserved (Zolla-Pazner and 
Cardozo, 2010). The third Env variable loop (V3 loop), which primarily dictates co-
receptor usage, binds directly to the chemokine protein (Kuiken et al., 1992; Carrillo and 
Ratner, 1996; Hoffman et al., 2002; Pastore et al., 2004; Pastore et al., 2006; Cardozo et 
al., 2007). CXCR4 co-receptor usage can require a minimum of 1-2 amino acid changes 




of the viral Env, such as variable loop 1 and 2 (V1/V2 loop), also play a role in co-
receptor usage (Carrillo and Ratner, 1996; Pastore et al., 2004; Pastore et al., 2006). 
CCR5-using viruses cause the majority of new HIV-1 infections, and these 
variants persist in all individuals throughout disease (Schuitemaker et al., 1992; van't 
Wout et al., 1994; Connor et al., 1997). CXCR4 variants have been found to emerge 
during the later stage of infection (Brumme et al., 2005; Moyle et al., 2005; Huang et al., 
2007). The emergence of CXCR4-using viruses has been associated with accelerated 
CD4+ T cell decline, faster progression towards AIDS, and poor prognosis 
(Schuitemaker et al., 1992).  
The prevalence of co-receptor switching varies among subtype and the rate at 
which this switch occurs for each subtype has been debated. Fueling the debate is the 
differing results found in early studies investigating the emergence of X4 viruses in 
different subtypes. One weakness of these earlier studies is the low number of study 
subjects used. Another, and perhaps the major driver of conflicting results is the differing 
stage of infection at which CXCR4-using viruses was measured (Zhang et al., 1996; 
Tscherning et al., 1998). One of the features of X4 virus emergence that is now generally 
accepted is that it emerges late in the course of HIV-1 infection, however, some earlier 
studies investigated the switch in co-receptor usage during the asymptomatic phase. 
Recently, an extensive literature analysis was performed to compare the use of CXCR4 
usage during the early asymptomatic disease stage to the late-stage of disease. This 
analysis revealed that X4 viruses emerge by the AIDS stage of infection in 54-76% of 




only emerge in 13 and 12% of individuals, respectively in these two subtypes (Fenyo et 
al., 2011). Recombinant strain CRF01_AE showed the highest frequency of X4 usage at 
76%. Subtype D, previously known to have the highest frequency of CXCR4 using 
viruses was found to occur in 70% of individuals.X4 emergence occurred at 62 and 64% 
in subtype B and recombinant strain CRF02_AG, respectively. Finally subtype A had a 
frequency of 54% (Fenyo et al., 2011).   
The mechanism for the shift in co-receptor usage remains unclear, however, 
several hypotheses have been proposed. Three non-mutually exclusive hypotheses have 
been primarily proposed to explain the emergence of CXCR4 co-receptor usage (Regoes 
and Bonhoeffer, 2005). These hypotheses are based on transmission and mutation, 
change in target cell, and loss of immune control. The first model posits that R5 viruses 
are initially transmitted, then through random mutations in the V3 loop, CXCR4 variants 
emerge and persist for varying reasons such as a waning immune response (Schellekens 
et al., 1990; Koot et al., 1993; Pastore et al., 2004; Regoes and Bonhoeffer, 2005). The 
second hypothesis argues that changes in the target cell population, such as a decline in 
cells susceptible to CCR5 infection, force the emergence of X4 viruses (Blaak et al., 
2000; Davenport et al., 2002; Harouse et al., 2003). Finally, investigations have 
postulated that relatively neutralization sensitive X4 viruses arise late during the chronic 
phase of disease with decreasing immune control, such as waning humoral immunity 
(Bunnik et al., 2007; Ho et al., 2007). All three hypotheses presume that emergence of X4 
viruses occur as a consequence of a diminution in the host response (Koot et al., 1993; 




however, have argued that CXCR4-utilizing variants emerge in the presence of humoral 
immune responses (Marcelino et al., 2012; Pfeifer et al., 2014; Lin et al., 2016).  
Humoral response to HIV-1 
B cell development 
 B cells develop from hematopoietic stem cells (HSCs) in the bone marrow (BM). 
Lymphoid progenitor cells receive signals from BM stromal cells to begin B cell 
development. Transcription factors Ikaros and EBF induce genes implicated in pre-B cell 
receptor (BCR) signaling (Eibel et al., 2014). B cell development occurs in three distinct 
stages. RAG1/RAG2 endonuclease initiates the early pro- B cell stage by rearranging the 
D and J segments of the heavy (H) chain. This is followed by the rearrangement and 
joining of the V gene to the D-JH segment to complete the late pro-B cell stage. The result 
of this stage is a µ-H chain (Pieper et al., 2013). Functional rearrangement of the µ-H 
chain allows the cell to enter the next phase. Functionality is tested by pairing of the µ-H 
chain with a surrogate light chain and Iga/Igb forming the pre-B cell receptor (pre-BCR). 
This is one of several checkpoints a B cell encounters in its maturation. Non-productive 
H chains are the result of frame shift mutations caused by the introduction of stop codons 
during VDJ recombination (Vettermann and Schlissel, 2010). Only a fraction of 
rearranged µ-H chains lead to functional B cells. A functional pre-BCR leads to allelic 
exclusion of the second H chain allele to prevent expression of two H chains with a 




At the pre-B cell stage, rearrangement of the gene segments encoding the k and l 
chains occur. Successful VkJk rearrangement leads to pairing with the µ-H chain which 
acts as a second checkpoint. The newly formed k-light chain is paired with the µ-H chain 
to form a BCR. Pre-B cells that are unable to pair with a µ-H chain or that form an 
autoreactive BCR undergo a second round of rearrangements. BCRs are down modulated 
from the surface and reenter the gene rearrangement phase. Rearrangement of the l chain 
can occur at this point by deletion of the Igk genes. B cells that do not yield a function 
BCR undergo apoptosis along with autoreactive antibodies (Vettermann and Schlissel, 
2010). The result of a functional BCR is an IgM molecule expressed on the cell surface 
and cells are now considered immature B cells.  
B cells circulate through blood and lymph but home to secondary lymphoid tissue 
such as the spleen, lymph nodes, tonsils, Peyers Patches, and mucosal tissues, specifically 
to the B cell follicles. Development of immature B cells is dependent on the migration of 
these cells to the spleen where they differentiate into B1, follicular, or marginal zone 
(MZ) B cells (Pieper et al., 2013). Follicular B cells localize to the lymphoid follicles of 
the spleen and lymph nodes. These cells are specialized in the response of protein 
antigens and are dependent on CD4+ T helper cell activation. MZ B cells form the 
marginal sinus of the spleen where they encounter blood-borne pathogens. B1 cells are 
located in the peritoneal and pleural cavities and mucosal sites. These cells specialize in 
surveillance of environmental pathogens in these tissues (Nutt et al., 2015).  
In a T cell-dependent response, germinal centers (GC) develop in B cell follicles 




cells and memory B cells. Upon presentation of antigen from follicular dendritic cells, B 
cells move to the edge of B cell follicle in search of T cell help. This movement is 
facilitated by upregulation of CCR7 that homes B cells to the boundary of the B cell 
follicle. Presentation of antigen to T cells delivers survival signals to B cells essential for 
B cell activation and differentiation  (Gatto and Brink, 2010; Takemori et al., 2014).  
These B cells initiate the antibody response by differentiating into plasma cells. 
Proliferation of these cells forms the GC where somatic hypermutation (SHM), affinity 
maturation, and antibody class switching occurs to rearrange the Ig variable region genes 
and produce high-affinity antibodies (discussed in Immunoglobulin development section) 
(Takemori et al., 2014; Nutt et al., 2015). Alternatively, B cells can migrate from the T 
cell-B cell area to extrafollicular space where they expand and differentiate into 
plasmablasts and plasma cells. Although some of these cells undergo class switching, this 
response is relatively unmutated and transient but provides the most immediate source of 
antibodies (Gatto and Brink, 2010; Zhang et al., 2016). After a humoral immune 
response, most B cells die, however, a small portion become memory cells or long-lived 
plasma cells. These cells persist for a long period of time and circulate through secondary 
lymphoid organs, colonize the marginal zone in the spleen, and BM. In the event of 
secondary exposure to a pathogen, memory B cells rapidly proliferate to provide 
protection against the pathogen  (Gatto and Brink, 2010). 
Antibody maturation 
 An antibody is composed of four polypeptide chains consisting of two heavy 




binding fragment is termed the Fab region while the effector function fragment is called 
the Fc region. The antibody repertoire is generated by assembly of the heavy and light 
chain genes in the immunoglobulin (Ig) loci during the development of B cells (discussed 
above). Within the heavy and light variable regions, there are three regions that are 
hypervariable, referred to as complementarity-determining regions (CDR), interspersed 
by regions of less variability, termed framework regions. The CDRs form the antibody-
binding site (Chiu and Gilliland, 2016). After antigen presentation and activation, mature 
B cells undergo SMH resulting in increased affinity. The process of SMH is initiated by 
activation-induced cytidine deaminase (AID). During SHM, AID deaminates cytosine 
residues in the heavy and light chains causing point mutations, insertions and deletions 
leading to a repair process. Affinity maturation is achieved as B cells, with SHMs that 
increase affinity of their BCR, are positively selected during multiple rounds of SHM, 
clonal expansion and affinity-based selection (Hwang et al., 2015).  
 Modifications are also made to the Fc region in the form of class 
switching.  The Fc region dictates the effector function of an antibody after it binds an 
antigen. Antibody class and subclass (IgM, IgD, IgG1-4, IgA1-2, and IgE) is determined 
by the constant region of the heavy chain. B cells exiting the BM express only IgM and 
IgD. Ig class is determined during an immune response and depends on the type of 
antigen and mode of entry. Constant regions, Cµ, Cd, Cg, Ce, Ca, are coded by the CH 
exon. Class switch recombination exchanges the Cµ with a different CH gene 
downstream. AID induces mutations that lead to the double strand breaks (DSB) 




desired constant region class (Xu et al., 2012). IgG is the most common serum antibody 
(85%), followed by IgA (7-15%), IgM (5%), IgD (0.3%) and IgE (0.02%) (Manz et al., 
2005). IgG promotes phagocytosis, IgE triggers mast cell degranulation, IgA surveys 
mucosal surfaces, and IgM/D activates the classical complement pathway (Hwang et al., 
2015). The half-life of most antibodies is less than 3 weeks. IgE has a short half-life of 
2.5 days (Manz et al., 2005).  
Isotype switching typically occurs after the B cell receives two signals, 
engagement of the CD40 receptor on B cells by T cell help and the appropriate cytokines. 
IL-4 has been shown to influence class switch from IgM to IgG. IL-10 and IL-13 have 
also been found to impact class switching to IgG, although to a lower extent. IgG 
subclasses are induced by different combinations of these three cytokines. IgG1 and IgG3 
are induced only in the presence of IL-10, however, IgG4 is induced by IL-4 and IL-13. 
IgE class switching also relies on the presence of IL-4 and IL-13 in combination (Tangye 
et al., 2002). Low levels of TGFb1 induce switching to IgA (Cerutti, 2008). IL-21 has 
been found to induce class switch to IgA and IgG, either alone, or in combination with 
IL-4 (Avery et al., 2008). HIV has been found to hijack this process by interrupting the 
signals needed for class switch to occur. HIV viral factor, Nef, has been found to induce 
negative feedback proteins IkBa and SOCS, which block CD154 (CD40 ligand) and 
cytokine signaling (Qiao et al., 2006).  





Several weeks after infection, a host begins to develop antibodies toward HIV-1. 
B cell responses develop about one week after viremia is detectable. The first response 
forms antigen-antibody complexes. Shortly after this initial response, IgM antibodies are 
generated against the gp41 and after a few weeks, gp120 and the V3 loop. These 
antibodies are at first non-neutralizing and exert no selective pressure on the virus 
(Overbaugh and Morris, 2012). As infection progresses, the antibody response sharpens 
and the first antibodies capable of neutralizing autologous virus arise months later. The 
earliest neutralizing antibodies have been detected around day 80 of infection 
(McMichael et al., 2010). The majority of the humoral response is directed against Env. 
IgG neutralizing antibodies against the external region of gp120/41 first appear in the 
plasma approximately 12 to 16 weeks after seroconversion (Euler and Schuitemaker, 
2012). The V1/V2 and V3 loop regions of the HIV-1 Env are a major target for 
autologous antibodies (Overbaugh and Morris, 2012). This response, however, is 
insufficient to block viral replication or clear infection (Deeks et al., 2006). In fact, 
autologous neutralizing antibodies have been found to be a source of select pressure 
leading to neutralization escape variants. Escape is caused by amino acid substitutions, 
insertions and deletions, and glycan shielding (Wei et al., 2003; Euler and Schuitemaker, 
2012; Overbaugh and Morris, 2012). A study by Moore et al. used quantitative PCR to 
track wild-type virus and the emerging viral variants. The group found that neutralizing 
antibodies decline viral load of the wild- type virus, however, emergence of escape 
variants occurred shortly after (Moore et al., 2009; Alter and Moody, 2010). This cycle is 




1. Several studies have examined whether HIV-1 humoral response can be protective and 
control viremia in particular settings; however, the results have been conflicting. Some 
studies have found that long-term non-progressors do generate neutralizing antibodies 
that contribute to the control of viremia, whereas, others have found no significant 
antibody activity in these individuals (Overbaugh and Morris, 2012).  
 Neutralization escape is only one route HIV-1 has developed to escape the 
immune response. The Nef protein of HIV is a virulence factor that plays several roles in 
HIV infection. One of those roles is to inhibit antibody class switching from IgD to IgG, 
IgE and IgA. HIV-specific IgA responses at mucosal sites and lymphoid tissues have 
been found to be low compared to other circulating classes of immunoglobulin (Qiao et 
al., 2006; Moir and Fauci, 2009). Mucosal sites and secondary lymphoid tissues are the 
primary sites of HIV-1 replication. The inability of the humoral response to control virus 
at the source of replication may also attribute to the ineffectiveness of the humoral 
response to reduce and control viremia systemically.  
BnAb targets and development 
While no individual has been found to have an adequate humoral response against 
HIV-1 capable of clearing infection, some individuals do develop broad cross-reactive 
antibodies against the virus. These bnAbs can neutralize heterologous viruses across 
subtype (Overbaugh and Morris, 2012; Bhiman and Lynch, 2017). BnAbs target multiple 
conserved regions of the HIV-1 viral Env. They can be placed into five main categories 
depending on the location of the epitope they bind, namely the apex, high mannose patch, 




membrane proximal region (McCoy and Burton, 2017). The apex is targeted by V1/V2 
loop directed antibodies that bind an asparagine (N)-linked glycan at position 160 
(Walker et al., 2009). Anti-variable loop 3 (V3 loop) bnAbs bind an N-linked glycan at 
position 332 in the high mannose patch on gp120 and interacts with nearby residues 
within the V3 loop (Julien et al., 2013). Since the identification of bnAbs and 
development of methods capable of scanning large cohorts, hundreds of potent bnAbs 
have been identified (McCoy and Burton, 2017).  
 The first investigations that demonstrated that human serum from HIV-1 infected 
individuals contained antibodies that could block infection of cells in vitro were done by 
1985. Very early on it was appreciated that the antibody response was generated against 
gp160. Later, several groups found that serum from some individuals was capable of 
neutralizing diverse primary HIV-1 strains. Between 1993 and 1994, the first monoclonal 
neutralizing antibodies, b12, 2G12, 2F5, and 4E10, were isolated against several regions 
of gp120 using phage display and human hybridoma electrofusion (Burton and 
Hangartner, 2016). These antibodies were found to completely block infection in 
macaques against SHIV infection. Structural and functional investigation of these 
antibodies lead to the discovery of unusual features that were thought to be detrimental to 
antibody survival. Some antibodies had novel domain swap configuration between 2 
heavy chains, some had long hydrophobic HCDR3 regions, some had features of 
polyreactivity and autoreactivity, and others had excessive somatic mutations (Mascola 




The early monoclonal neutralizing antibodies did not have much breadth and/or 
potency. They could not neutralize a majority of HIV-1 strains. Both 2G12 and b12 
neutralized less than 50% of viruses that they were tested against. BnAb discovery was 
made possible by two major developments. One was the development of a high-
throughput method based on the construction of recombinant Env pseudoviruses to test 
antibody neutralization. This gave researchers the ability to analyze serum and antibodies 
against large panels of viruses. The second was the development of single B-cell 
approaches to isolate human antibodies. Using limiting dilutions, close to single B cells 
(2-4 cells per well) could be cultured in individual wells. The Ig secreted in each well can 
then be directly tested for HIV neutralization. Antibody from wells that neutralize virus 
above a set threshold are recovered by PCR amplification of the heavy and light chains 
and cloned into an IgG expression vector. A second approach involves using 
fluorescently labeled Env-specific proteins as probes to identify and sort HIV-1 specific 
B cells from the individuals wells and recover the antibody using PCR and cloning. The 
first bnAbs, PG9 and PG16, were described in 2009. Hundreds of bnAbs have since been 
identified with much greater potency and breath since then (Mascola and Haynes, 2013). 
BnAbs as treatment 
 The discovery and use of bnAbs over the last several years has grown 
tremendously. Along with providing a framework for developing an HIV-1 vaccine, 
bnAbs are also being investigated as a potential therapeutic (Bhiman and Lynch, 2017). 
Non-human primate (NHP) studies show that passive immunization with bnAbs could 




rhesus macaques (RMs) infected with simian-human immunodeficiency virus (SHIV)AD8 
or SHIVSF162P3 (Barouch et al., 2013; Shingai et al., 2013; Bolton et al., 2015; Hessell et 
al., 2016; Nishimura et al., 2017). Various combinations of bnAbs PGT121, 3BNC117, 
b12, and VRC01 were tested as treatment for infection in these studies. In each study, 
monkeys were treated with either a mono-infusion or a combination of bnAbs during 
various phases of SHIV infection. Three studies examined the effects of bnAb treatment 
early in infection, from day 1-10 (Hessell et al., 2010; Bolton et al., 2015; Nishimura et 
al., 2017). In each case, bnAbs were capable of suppressing viremia. Virus did rebound, 
however, in 2 of the 3 studies (Bolton et al., 2015; Nishimura et al., 2017). In the third 
study, bnAb infused RMs had no detectable viremia in tissues on day 14 and even though 
low levels of SHIV DNA were detected in the mucosa and lymph nodes, no viremia was 
detected in plasma after that time point (Hessell et al., 2016). The remaining two studies 
examined the effects of bnAb treatment 3, 9, or 36 months after infection (Barouch et al., 
2013; Shingai et al., 2013). In each group, RMs showed suppression after bnAb infusion 
before viral loads began to increase. Three of 18 treated animals in the 9-month study 
experienced long-term viral control of viral replication for periods, even after antibody 
titers were undetectable (Barouch et al., 2013). In both studies, single genome 
amplification (SGA) of rebounded virus showed that no resistance mutations arose, with 
the exception of monotherapy with 10-1074, in which case loss of the N332 glycan was 
observed (Shingai et al., 2013). Collectively, these non-human primate studies 




The successes of NHP studies paved the way for human clinical trials. To date, 
six studies using monotherapy of VRC01, 3BNC117, and 10-1074 have been completed 
in chronically infected individuals and one phase one trial in healthy adults(Scheid et al., 
2011; Caskey et al., 2015; Ledgerwood et al., 2015; Lynch et al., 2015; Scheid et al., 
2016; Schoofs et al., 2016; Caskey et al., 2017). In most instances, these human trials 
recapitulated the findings of the NHP studies. Transient suppression or reduction in 
viremia was achieved at the highest concentration administered, 30-40 mg/kg, in 
comparison to the 10-20 mg/kg needed to reach suppression in the macaque studies. Just 
as bnAb combination therapy was associated with longer suppression of viremia and 
lower viral load (VL), it is expected that combination therapy in humans will overcome 
some of the shortcomings of monotherapy (Bhiman and Lynch, 2017).  
In addition to the discovery of antibodies that are broadly neutralizing, many 
advances have been made in the modification of antibodies. Antibody engineering can 
optimize an antibody by increasing affinity of an antibody to its antigen, binding to a 
second epitope (bispecific antibodies), specify an effector function, increase potency, and 
increase half-life. Half-life is increased by Fc modifications that allow stronger binding to 
Fc receptor (Sievers et al., 2015; Chiu and Gilliland, 2016). B12, one of the first bnAbs, 
was modified to increase affinity by 400-fold (Yang et al., 1995). Antibody engineering 
could generate more potent bnAbs to lower dose concentrations, reduced cost, cut 
production time, and increase time between the treatment. HIV-1 therapy could be 
revolutionized from once a day ARV to once a month bnAb infusion with the successful 




Scientific proposal and hypothesis 
The following work seeks to elucidate the interaction between HIV-1 Env co-
receptor usage and antibodies. We investigated the role of the humoral immune response 
against HIV-1B on the emergence of CXCR4 co-receptor usage. We hypothesized that 
X4 viruses are neutralization escape variants and arise due to pressure from V3 loop 
directed antibodies. This hypothesis has implications for the use of bnAbs for the 
treatment of HIV-1 infection. We, therefore, investigated the role of co-receptor usage on 
neutralization sensitivity to bnAbs. We further aimed to develop a prediction tool that 
could predict susceptibility to bnAbs. These studies will further our basic understanding 
of how changes in the co-receptor binding region of HIV-1B impacts the ability of 
antibodies to bind and neutralize the virus. To investigate our hypothesis, the following 
aims are proposed: 
 
Aim 1: Examine the role of selective pressure on the emergence of CXCR4-using viruses. 
  Development of CXCR4 co-receptor usage is associated with advanced disease 
progression. The mechanism in which this switch in co-receptor usage occurs is not yet 
clearly understood. Although several theories have been proposed as possible 
mechanisms, none fully explain both the emergence and persistence of the X4 viruses. 
Furthermore, it has been presumed that X4 viruses arise in the absence of a humoral 
immune response. Preliminary data from our lab, however, indicate that X4 viruses may 
arise from selective pressure. In this aim, we would like to explore the possibility that 




V3 loop dictates co-receptor usage. These experiments will further our understanding of 
the mechanism for the emergence of CXCR4 co-receptor usage and the humoral immune 
response in individuals bearing X4 viruses.  
 
Aim 2: Examine the role of co-receptor usage on neutralization sensitivity to broadly 
neutralizing antibodies.  
V3 loop directed broadly neutralizing antibodies primarily bind to glycans at the 
base of the V3 loop but can also interact with amino acids residues within the loop. Our 
hypothesis that X4 viruses arise as neutralization escape variants has possible 
implications for the ability of those bnAbs that bind Env epitopes governing co-receptor 
usage.  These include the V1/V2 loop-specific bnAbs. We hypothesize that X4 as 
compared to R5 viruses will be less neutralization sensitive to V1/V2 and V3 loop 
directed bnAbs. In this aim, we will compare neutralization sensitivity of X4 and R5 
viruses to bnAbs spanning the HIV-1 Env. This aim will elucidate the relationship 
between co-receptor usage and neutralization susceptibility for the future use of bnAbs as 
treatment. 
 
Aim 3: Develop a tool to predict susceptibility to broadly neutralizing antibodies.  
The discovery of HIV-1 broadly neutralizing antibodies has opened a new arena 
for therapeutics against HIV-1. Early clinical trials show promise that bnAbs can reduce 
viremia for several weeks in individuals without pretreatment resistance. Unlike ARVs, 




genotype or phenotype based assay, no rapid options exist for clinical use. In this aim, we 
will investigate structural differences between viruses with opposing neutralization 




CHAPTER TWO: Materials and Methods 
ACTG A5095 Study 
Study information and subjects 
Patient samples were collected from the AIDS Clinical Trials Group (ACTG) 
Study A5095, a randomized, double blind trial assessing different antiretroviral regimens 
for the initial treatment of HIV-1. Eligible patients were adults who had not previously 
received antiretroviral therapy and who had plasma HIV-1 RNA levels of at least 400 
copies per milliliter at the start of the study. RNA levels were measured using HIV-1 
Monitor Assay (HIV-1 Monitor Assay, version 1.0, Roche Molecular Systems). 
Baseline tests included a medical history, clinical assessment, laboratory test, plasma 
HIV-1 RNA levels, CD4+ cell count and plasma sample. Plasma samples, HIV-1 RNA 
levels, and CD4+ cell count were made available for our study.   
Cell lines 
Human epithelial kidney (HEK) 293T (103) and TZM-bl cells (8129) were 
acquired from the NIH AIDS Reagent Program. 293T and TZM-bl cells were maintained 
in Dulbecco’s modified Eagle medium (DMEM) (Fisher, MT-10-017-CV) complete 
media, composed of 86% DMEM, 10% heat-inactivated fetal bovine serum (FBS) 
(Fisher, 35010CV), 2 mM L-glutamine (Fisher, MI-25005CI), 2% Pen/Strep (100 U/mL 
of penicillin and 100 µg/mL of streptomycin) (Fisher, 15-140-163), and 1% hepes 






HIV-1 RNA was isolated from 140 μl of each sample using the QIAamp viral RNA Mini 
kit (Qiagen, 52904) using the manufacturer protocol.  
cDNA synthesis 
RNA was reverse transcribed using Superscript III Reverse Transcriptase (SSIII 
RT) (Invitrogen, 18080-044) to make cDNA using CHAVI-MBSC-1 Protocol (SOP#: 
CHAVI-MBSC-2). Primer used for reverse transcription was envB5out 5’-
TAGAGCCCTGGAAGCATCCAGGAAG. Each reaction included 30 µl of RNA 
template, 0.5 mM dNTP mix (Invitrogen, 10297018), 0.25 mM of primer (Invitrogen), 
and 5.25 μl RNA grade water (Fisher, BP561-1). Each reaction was incubated at 65° C 
for 3-5 mins and then on ice for 1 min. A second master mix of 5x buffer, 5 mM DTT, 2 
mM RNaseOUT (Invitrogen, 10777-019), and 10 U/μl of SSIII RT were added for a final 
volume of 60 μl. This reaction was incubated at 50° C for 1 h and then increased to 55° C 
for 1 h. SSIII RT was inactivated by heating at 70° C for 15 mins. Lastly, 3 μl of RNase 
H (New England Biolabs, M0297S) was added and incubated at 37° C for 20 mins. The 
final product was aliquoted into 10 µl volume and stored at -80°C until further use.  
Real-time PCR 
Real-time PCR was used to determine HIV copy number to compute the 
appropriate dilution for SGA that would achieve a maximum of 30 positive PCR 




representative of reaction beginning with 1 genome template based on Poisson frequency 
(Butler et al., 2009).Each reaction contained 10% Buffer A, 25 nM MgCl2, 2 mM dNTP, 
100 ng/µl Pol primers (Invitrogen), Pol 4 5’-CTGCCCCTTCACCTTTCC and Pol 15 5’- 
TACAGTGCAGGGGAAAGAATA, 1% Pol probe (Invitrogen), 5 U/µl TAQ Gold 
(Invitrogen, N8080243), and water to 40 µl. cDNA was diluted 1:10 in water. 10 µl was 
added per well to 40 µl of master mix. All experiments were carried out in triplicate. 
Cycle number was used in web-based tool- sgacalc.usdc.edu to predict the appropriate 
amount of cDNA to use in SGA.          
Single genome amplification 
For first round single genome amplification (SGA), diluted cDNA was added to 
0.025 U/μl of Platinum Taq High Fidelity (Invitrogen, 11304102), 200 μl of 10x buffer, 2 
mM of MgSO4, 0.2 mM of dNTPs, and 0.2 μM of forward and reverse primers in a 20 µl 
reaction. Forward and reverse primers for first around PCR were envB5out and envB3out 
5’- TTGCTACTTGTGATTGCTCCATGT. 1 μl of the first-round product was added to a 
fresh master mix for the second round. Second round primers were envB5in 5’-
TTAGGCATCTCCTATGGCAGGAAGAAG and envB3in 5’- 
GTCTCGAGATACTGCTCCCACCC. Cycling conditions for the first round were as 
follows: 94° C for 2 min, followed by 94° C for 15 s, 55° C for 30 s, then 68° C for 4 min 
for 35 cycles, followed by a final extension at 68° C for 10 mins. For the second round 
the number of cycles was increased to 45 cycles. SGA products were sized on a 0.7% 





All SGA plates yielding less than 30% PCR positivity were purified for 
sequencing using ExoSap IT (Affymetrix, 78201). All products were initially sent for 
sequencing with V3 loop primers Env110 or Env115. Envs from subjects with predicted 
co-circulating X4 and R5 using viruses (see web prediction tools section below) were 
then sent for further sequencing with primers that spanned the full Env (see primers 















Table 2.1. Primers for full Env sequencing 
Web prediction tools 
The genotype of each Env was predicted from the V3 loop sequence using either 
WebPSSM (https://indra.mullins.microbiol.washington.edu/webpssm/) (Jensen et al., 
2003) using subtype B x4r5 setting or Geno2Pheno 
(http://coreceptor.geno2pheno.org/index.php) at a false predication rate of 5%. These two 
web tools represent the two most widely used genotypic prediction algorithms. Genotype 




Yeast gap repair and plasmid rescue 
Predicted R5 and X4 using Envs were inserted into a NL4-3 backbone plasmid 
using yeast gap-repair homologous recombination. 100 µl of lab grown competent yeast 
cells stored at -80°C were thawed and centrifuged for no more than 30 s at top speed 
(13K rpm) and supernatant discarded. 67 µl of water was used to re-suspend cells. A 
master mix of 1 µg SGA product, 0.2 µg linearized pCMV-NL4-3- PBS→LTRGp160 
plasmid, 10 µl of 10 mg/mL salmon sperm DNA heat inactivated at 95°C (Stratagene, 
201190), 36 µl 1M lithium acetate, and 240 µl 50% sterile PEG (Fisher, P146-3). The 
yeast mixture was incubated at 30°C for 30 mins then transferred to 42°C for 15 mins. 
The mixture was centrifuged for 30 s and the supernatant discarded. Cells were re-
suspended in 100µl of TE buffer and plated on –Leu + FoA plates. This selection allowed 
for the growth of only the transformed yeast cells that now have desired HIV-1 Env in 
place of URA3. FoA is converted to the toxic compound 5-fluorouracil by the URA3 
gene. Cells that did not replace this gene with the HIV-1 Env will die. –Leu plates/media 
allows growth only when the HIV plasmid containing the leucine gene is transformed 
into the yeast (Dudley et al., 2009). One colony was picked into 2 mL -Leu media and 
shaken overnight at 30°C. The following day, the yeast culture was transferred to a screw 
top tube and centrifuged for 30 s. The supernatant was aspirated and cells were re-
suspended in 200 µl yeast lysis buffer. 200 µl 0.45 mm acid wash beads (Sigma, G8772) 
and 200 µl phenol/chloroform (Fisher, BP17521-100) were added to cells. The mixture 




temperature (RT). The top layer was transferred to a new 1.5 mL tube. 1/10 volume of 3 
M sodium acetate and 2.5 volume of 100% ethanol (Sigma 459836-2L) were added then 
mixed. The mixture was incubated for 20 mins at -80°C and centrifuged at top speed for 
20 mins. The supernatant was decanted and the pellet dried at 42°C for 1 min. The pellet 
was resolved in 100 µl water overnight.  
Bacterial transformation 
1-2 µl of recovered plasmid from yeast gap repair was added into a thawed tube 
of 50 µl of lab grown Top10 electrocompetent E. coli cells. The mixture was transferred 
into a chilled cuvette (Fisher, FB101), electroporated, then transferred into 150 µl of SOC 
media (Invitrogen, 15544-034) in a 2 mL tube. The culture was shaken for 1 h at 30°C 
then transferred to a LB amp plate. One colony was picked and transferred to 2 mL of LB 
AMP media overnight shaking at 30°. Plasmid was rescued using Qiaprep Miniprep kit 
(Qiagen, 27106) by following manufacturer protocol. 
293T Transfection 
 Two million 293T cells were plated in a six well plate overnight. Cells were used 
for transfection when they reached 20-30% confluency. The next day, a total of 2 µg of 
DNA at 1:3 ratio of recovered recombinant plasmid to helper plasmid pCMV-NL4-3 
LTR-gag4 were added to one tube. Full length pCMV-NL4-3 was used as a transfection 
positive control. One well was left empty to be used as a negative control. DMEM only 
was added to 100 µl total volume. In a second tube, 6 µl Fugene transfection reagent 




mins. The tube with DNA was added to the Fugene tube and incubated for 15 mins at RT. 
The Fugene and DNA mixture was added dropwise to 293T cells and incubated for 48 
hours at 37°C. Supernatants were collected, filtered through 0.45 µM filter (Fisher, 
SLHV033RB) to remove cell debris, then stored at -80° before titration.  
TZM-Bl Titration 
Viral supernatant was titered using TZM-bl titration assay. TZM-bl cells were 
suspended at 1 x 106 cells/10 mL, plus 10 µl 20 mg/mL DEAE-Dextran (Fisher, 
ICN19513310). In a 96 well black Costar plate (Fisher, 07-200-588), 100 µl DMEM 
complete was added to each well. 100 µl of virus from 293T transfection was added to 
row A and serially diluted 2-fold to row G. A lab adapted virus was used as a positive 
plate control and wells containing no virus was used as a negative control. 100 µl of cell 
suspension was added per well. Each condition was tested in triplicate. The plate was 
incubated at 37°C 48 hours. Plates were then read for relative light units (RLU) using 
beta-galactosidase assay (see section below). Titer was calculated by subtracting the 
negative control from each well then averaging the values of the three replicates.  
Beta-galactosidase assay 
TZM-Bl cells contain a beta-galactosidase (beta-gal) gene driven by a promoter 
activated by the tat protein. Upon infection with HIV-1, beta-gal is released and 
measured as a read out of infection using Galacto-Light Plus Systems (Invitrogen, 
T1009). After 48 hours of infection of TZM-Bl cells, the supernatant was removed and 




added into each well. The plate was shaken at RT for 10 mins. During 10 min incubation, 
the substrate was diluted 1:100 using the provided diluent. 70 µl substrate was added into 
each well and the plate was returning to the shaker for 1 h. 100 µl of accelerator II 
(provided in kit) was added to each well and RLU was measured immediately.  
 
Co-receptor analysis 
Co-receptor usage was determined using a drug inhibition assay. TZM-bl cells 
were plated in a 96 well plate with either DMEM complete media, media with 800 nM 
TAK779, a CCR5 inhibitor, media with 800 nM AMD3100, a CXCR4 inhibitor, or 
media with TAK779 and AMD3100. Virus was added to the culture and beta-
galactosidase activity was measured 48 hours later. Each condition was tested in 
triplicate. All assays were performed with known phenotype controls, NL4-3 (X4), YU2 
(R5), and 89.6 (R5X4). Co-receptor usage was assigned based on statistically significant 
relative light unit differences observed in the presence as compared to the absence of 
specific inhibitors. 
Phylogenetic Analysis 
Maximum likelihood trees were generated using PhyML v3.0. Sequence files 
consisted of nucleotide alignments of gp120 open reading frame. Mega6 Find Best 
DNA/Protein Models was used to determine the best-fit evolutionary model. General 
time reversal was selected as the substitution model. Equilibrium frequencies were 
estimated using an empirical method. Starting tree was based on BioNJ. NL4-3 was 




PBMC isolation and infection 
Peripheral blood mononuclear cells (PBMCs) were separated and purified from 
whole blood using Ficoll (Fisher, 45-001-749) gradient separation. PBMCs were 
propagated in Roswell Park Memorial Institute medium (RPMI) (Fisher, MT-10-040-CV) 
containing 10% FBS, 100 µg/mL penicillin-streptomycin, 5 µg/mL of 
phytohemagglutinin (Fisher, R30852801) and 20 U/mL interleukin-2 (IL-2) (Roche, 
11147528001) for 4 days prior to infection. On day 4, PMBCs were washed with PBS, 
pelleted, and incubated with .5 mL of 293T virus and 1:1000 DEAE Dextran 
(ICN19513310) for 4h. The culture was then increased to 2 x 10e6 cells/mL with 1:5000 
of IL-2 and incubated for 7 days. Cultures were filtered, aliquoted, and store at -80°C 
before TZM-bl titration.   
	 	
Chimeric virus synthesis 
Chimeric viruses were produced using an overlapping PCR strategy. Head 
(beginning of gp120 to end of V1/V2) and tail (C2 to end of gp120) fragments were 
amplified from plasmids incorporating the full-length envelope. Head and tail fragments 
were amplified using primers listed below and the following cycling program: 94° C for 2 
min, followed by 94° C for 15 s, 53° C for 30 s, then 68° C for 2 min 30 s for 20 cycles, 
followed by a final extension at 68° C for 5 mins. Overhangs were inserted at the ends of 
each fragment except for the 5’ end of the head piece and the 3’ end of the tail piece by 
the same PCR conditions used to amplify the fragment. Overhang primers were designed 




then cleaned using Qiagen PCR purification kit (Qiagen, Fb-6000-65). The two pieces 
were assembled into a chimeric sequence. In a total of 20 µl, head and tail products were 
added together with Pfu Turbo polymerase (Fisher, 50-125-978), Platinum Taq 
polymerase, MgSO4, dNTP, Pfu Turbo buffer, Taq buffer and water. 1 µl of PCR product 
was added to a fresh reaction as described for SGA with the same cycling conditions as 
2nd round SGA. Primers used were EnvIF-5’- 
AGAAAGAGCAGAAGACAGTGGCAATGA and EnvIR-5’- 
AGAAAGAGCAGAAGACAGTGGCAATGA. The PCR product was cleaned by 
ExoSap reaction and sent for sequencing using primers that span the Env. Virus was 




Env OF GGCTTAGGCATCTCCTATGGCAGGAAGAA 

















Global panel virus synthesis 
 Expression plasmids for the 12 rev-env cassettes selected as a global panel of 
reference stains for the examination of antibody breadth and potency was obtained from 
the NIH AIDS Reagent Program (www.aidsreagent.org) (see table below for catalog 
numbers) (deCamp et al., 2014). Envs were inserted into an NL4-3 plasmid and 
replication competent viruses were generated as described above. A replication 
competent virus could not be generated for Env CE0217, and therefore, the global panel 
used in this study only contained 11 of the 12 viruses.  













Table 2.3. Reference strains for global panel 
Neutralization assay and analysis 
Neutralization sensitivity of the generated recombinant viruses was tested with the 
TZM-bl cell assay. TZM-bl cells were exposed to the recombinant virus in the presence 
of 2-fold serial dilutions of plasma or varying starting concentrations of antibody. Plasma 




of 1:50. Antibody samples were also tested in triplicate. All plasma was heat inactivated 
in a 56° bath for 1 h to prevent subsequent complement mediated inhibition. Beta-
galactosidase activity was measured to quantify reductions in virus infection in presence 





where RLUt denote RLU for test (cells + virus + antibody), RLUc denotes cell control 
(cells only) and RLUv virus control (virus + cells but no antibody sample) wells. A 
neutralization curve was generated by plotting neutralization against antibody or plasma 
concentration. A line was fitted to the curve and β values calculated for a second order 
quadratic polynomial model in GraphPad Prism: 
f (x, β) = β1 + β2x + β3x2 . 
β values were then used to calculate AUC as the average neutralization within the 







(𝑥1-+x1xn +𝑥2-).  




Neutralization against the global reference Env and the CXCR4-using Env panel was 
assessed only at 1 plasma dilution (1:50). Breadth and potency (BP) score were 
calculated using the equation: 




BP scores ranged from 0 to 1. A score of 0 represents no neutralization and a score of 1 
represents 100% neutralization. Heat maps were generated using the Los Alamos HIV 
sequence database heat map tool (https://www.hiv.lanl.gov/). All heat maps used 
hierarchical clustering with the Euclidean distance method.  
Structural modeling 
Models of X4- and R5-utilizing Envs were produced using Rosetta software made 
available by Robetta Structural Prediction Server online (Song et al., 2013). Amino acid 
sequences submitted to the Robetta online server (http://robetta.bakerlab.org/submit.jsp). 
Once a Ginzu Domain Prediction was made, domain 1 of prediction 1 was selected to be 
modeled using comparative modeling. The number one ranked model was selected for 
each Env. Structural models of 1 co-circulating X4 and R5 V3 loop were made for each 
subject and superimposed on top of each other. Docking of the CCR5 chemokine receptor 
with R5 and X4 V3 loops were done using Cluspro (Kozakov et al., 2017). All 
superimpositions were done using Pymol software (The PyMOL Molecular Graphics 
System, Version 2.0 Schrödinger, LLC).  
Statistical analyses 
	
AUC and IC50 values represent the mean of 2 independent assays. Comparisons 
between groups containing independent data points were done using the Mann-Whitney 
test. Comparisons between groups containing matched samples were done with the 




Spearman correlation. All statistical analysis was done using GraphPad Prism 5.0. All p-
values are based on two sided tests.  
Lab grown competent cells 
Competent Top 10 E. coli cells 
Grow 5 mL culture of Top10 in LB broth in the absence of ampicillin overnight at 
30°C. Split 5 mL culture: 2.5 mL in 1 L and 1.25 mL in 2 500 mL LB broth flasks. Grow 
at 30°C for about 4 h, and check OD. An OD≤0.400 is ultimate for extraction. Centrifuge 
at 6000 rpm for 10 min at 4°C. Wash 3x with autoclaved ddH2O for 5min. Re-suspend in 
2.5 mL of 30%glycerol. Aliquot 50 µl in 0.65 mL tubes. Store at –80°C. 
Competent yeast cells 
Saccharomyces cerevisiae Hanson (MYA-906), MAT α ade6 can1 his3 leu2 trp1 
URA3 was grown using the following protocol: Start 5 mL culture of yeast in YEPD was 
started overnight at 30°C. Add about 2 mL of 5 mL culture a 250 mL flask of YEPD and 
shake at 30°C overnight. Inoculate 500 mL with ~ 1 mL of the 250 mL culture and shake 
at 30°C for 12-15 hours, until OD reaches 1.2. Centrifuge the culture at 3000 rpm for 5 
min in 50 mL sterile conical tubes. 
Wash 2x with ddH2O. Re-suspend the yeast pellet in 1 mL sterile 10% glycerol for every 
50 mL of original 1.2 OD yeast culture. Aliquot 100 µl of the re-suspended yeast pellet 






Buffers and reagents 
LB media 
To 1 L ddH2O: 10g Tryptone, 10g NaCl, 5 g Yeast extract, adjust pH to 7 with NaOH 
pellets. Mix and autoclave for 30 mins. Add 100 µg/mL ampicillin when cooled.  
LB Amp plates 
To 1 L ddH2O: 40 g LB Agar. Mix and autoclave. Cool to 55° C and add 100 µg/mL 
ampicillin. Mix and pour plates.  
-Leu media 
To 1 L ddH2O: 6.7 g Yeast nitrogen base, 20 g Dextrose, and 0.69 g –Leu CSM media. 
Mix and autoclave.  
-Leu + FOA plates 
To 500 mL ddH2O: 20 g Agar, 6.7g YNB with ammonium sulfate, 0.69 g –Leu CSM 
media. Mix and autoclave. 
To 350 mL ddH2O: 20 g dextrose, 1 g 5-FOA. Adjust voluve to 500 µl, mix and filter.  
Mix solutions and pour plates. Store plates in the dark.  
50x TAE buffer  
To 600 mL ddH2O: 242 g Tris base, 57.1 mL glacial acetic acid, 100 mL 0.5M EDTA 




Yeast Lysis buffer 




To 1 L ddH2O: 10 g Yeast extract, 20 g Peptone, 20 g Dextrose. Mix and autoclave.  
10x TE buffer 
To 880 mL ddH2O: 100 mL of 1M Tris-Cl, 20 mL of 0.5M EDTA, pH 8.0. Mix and 





CHAPTER THREE: Specific HIV-1 envelope genotypic, structural and 
neutralization characteristics associate with CXCR4-usage 
 Background 
 The emergence of CXCR4-using viruses has been presumed to occur as a 
consequence of a diminution in the host antibody response and is associated with 
accelerated CD4+ T cell decline (Schuitemaker et al., 1992; Koot et al., 1993; Richman 
and Bozzette, 1994; Daar et al., 2007; Goetz et al., 2009). Our group and others, 
however, have argued that CXCR4-utilizing variants emerge in the presence of humoral 
immune responses (Marcelino et al., 2012; Pfeifer et al., 2014; Lin et al., 2016). While 
the mechanism for the shift in co-receptor usage remains unclear, association with 
humoral responses could have implications for future antibody therapies.  
In response to HIV-1 infection, the host mounts a humoral immune response 
against the virus. Autologous neutralizing antibodies are produced within weeks of 
seroconversion (Moore et al., 1994; Legrand et al., 1997; Moog et al., 1997; Gray et al., 
2007). These autologous neutralizing antibodies frequently target the Env V3 loop 
(Moody et al., 2015). We have previously found that individuals harboring a mixture of 
R5 and CXCR4-using viruses had greater Env sequence diversity in the V1-V2 and V3 
loop as compared to individuals harboring only R5-using viruses (Lin et al., 2012). We 
have argued that autologous antibody pressure drives this observed increased genetic 
diversity, and thus humoral responses are potentially associated with the presence of 
CXCR4-using viruses (Lin et al., 2016). A recent investigation also suggests that both 




responses influences sensitivity to different interferon-induced transmembrane proteins 
(IFITMs), implying there is a linkage between co-receptor use and humoral immunity 
(Foster et al., 2016). We, therefore, hypothesized that CXCR4-using viruses are 
neutralization escape variants and arise due to humoral immune pressure. We used 
sequence analysis, structural modeling, and neutralization assessments to provide further 
insight into the role of antibodies and co-receptor switching.  
Results 
3.1 Subjects and sequences.  
  Samples that were previously characterized as DM, using both bulk-PCR V3 
sequence and bulk Env virus pseudotype phenotypic analysis, were obtained from 32 
anti-retroviral naïve subjects enrolled in the AIDS Clinical Trials Group (ACTG) A5095 
study (Gulick et al., 2004; Henrich et al., 2014). One additional sample (SC) that was not 
part of this ACTG study was collected from an individual who was on combination 
antiretroviral treatment (c-ART). A total of 929 individual Envs (median=16 Envs per 
subject, range= 1-239) were isolated from the samples using SGA. A web-based 
prediction tool, either WebPSSM or geno2pheno, was used to predict the co-receptor 
usage of the isolated Envs based on the V3 loop sequence (Jensen et al., 2003; Lengauer 
et al., 2007). A mixture of predicted CXCR4-using and R5 Envs were isolated from 14 
individuals. All SGA isolated Envs from 9 other individuals were predicted to use the 
CXCR4 receptor (either R5X4 or X4). In the remaining 10 DM samples, all isolated Envs 
were predicted to utilize the CCR5 receptor exclusively, and Envs able to use both co-




to the bulk PCR analysis. Fifteen samples in which predicted CXCR4-using Envs were 
successfully isolated were examined further (Table 3.1). 
 
Subject # Envs 
isolated 




# of SGA Envs with confirmed 
phenotype 
R5 CXCR4 R5 X4 R5X4 
4102 61 52 9 19 13 5 1 
1239 239 234 5 12 9 1 2 
1233 101 72 29 10 7 3 0 
3248 16 0 16 9 0 9 0 
1924 27 24 3 2 1 1 0 
3576 30 0 30 6 0 6 0 
3131 17 6 11 7 7 0 0 
1069 10 0 10 9 9 0 0 
2327 6 0 6 4 1 0 3 
0229 40 5 35 7 3 0 4 
1045 16 6 10 7 7 0 0 
SC 11 7 4 6 5 0 1 
1389 15 0 15 7 1 0 6 
1486 15 7 8 5 5 0 0 
3026 110 109 1 4 4 0 0 





3.2 X4 viruses have distinct V3 loop features. 
The web-based genotype prediction tools do not distinguish between a R5X4 and 
a X4 Env. To overcome this deficiency, a subset of SGA isolated Envs from 15 samples 
were incorporated into an NL4-3 backbone to generate replication-competent viruses 
(Table 3.1, Fig 3.1). Virus stocks were examined for co-receptor usage in a TZM-bl cell 
based phenotypic assay in the presence and absence of receptor inhibitors. Six of those 15 
samples contained X4 variants (Table 3.1). A mixture of R5 and R5X4 but not X4 viruses 
were isolated from 4 individuals. Interestingly, the virus stocks incorporating SGA Envs 
from the remaining 5 subjects only demonstrated CCR5 usage even though some of the 
Envs were predicted to use the CXCR4 receptor by genotype based tools. These 
observations confirm that genotype based prediction tools often misclassify Envs. 
Sequence alignment of 25 X4, 17 R5X4, and 72 R5 phenotypically confirmed 
viruses revealed that all of the X4 variants except 1924 contained a 2 to 3 amino acid 
insertion in the V3 loop (Fig 3.2). Insertions were observed either directly before the 
glycine-proline-glycine (GPG) crown or toward the base of the V3 loop. Insertions 
directly before the GPG crown were either glycine-isoleucine (GI) or glycine-histidine-
isoleucine (GHI). A phenylalanine-methionine (FM) insertion along with a methionine 
(M) insertion was observed in all X4 Envs that did not contain changes prior to the GPG 
crown (Fig 3.2). Subject 1233 harbored X4 variants with both types of the observed 
insertions. These specific V3 modifications were not found in any of the amplified 
phenotypically confirmed R5 or R5X4 Envs. A search of the Los Alamos Database for 




multiple sequences with this motif have been deposited previously, however, co-receptor 
usage was not listed for any of them (Table 3.2). Based on these observations, we 
conclude that the observed V3 loop insertions are highly specific for viruses that 






Figure 3.1. Approach to generate replication competent viruses. 
Schematic represents the work flow to generate replication competent viruses. RNA was 
extracted from plasma samples and immediately used to generate cDNA. SGA was 
performed to generate single env amplicons per well. SGA plates that yielded 30% 
positive wells or less were collected and genotyped by sequencing. Co-receptor usage 
was predicted using web predication tool, WebPSSM. Selected predicted R5 and X4- 
using envs were inserted into an NL4-3 backbone using yeast recombination methods. 
The resulting virus construct was transfected into 293T cells and propagated in PBMC’s 
to generate high titer replication competent viruses. Genotype was confirmed by co-















1 X4 C T R P S K N - V K R M I H I G H I G G G R A W H T T E K I T G N - - L R - P H C
5 X4 C T R P S K S - I K R M I H I G H I G G G R A W H T T E K I T G N - - L R - P H C
3248
1 X4 C T R P D N K M K K R I I H I - - - G P G R T F Y T A K K E X K D F M L R Q A R C
1 X4 C T R P D N K M K K R I I H I - - - G P G R T F Y T A K K E V K D F M L R Q A H C
1 X4 C T R P D N K M T K R I I N I - - - G P G R A F Y T V T K K M K G F M L R Q A R C
5 X4 C T R P D N K M T R R I I H I - - - G P G R T F Y T A K K E - K D F M L R Q A R C
1 X4 C T R P D N K M T K R I I H I - - - G P G R A F Y T A K K E - K D F M L R Q A R C
1239
1 X4 C T R P N N N - T R K S V R I G - I G R G R A W S R T T D I I G D - - I R Q A H C
2 DM C T R P N N N - T R K G I N I - - - G P G R A W Y R T T D I I G D - - I R Q A H C
1 R5 C T R P N N N - T R K G I N I - - - G P G K A W Y R T T D I I G D - - I R Q A H C
8 R5 C T R P N N N - T R K G I N I - - - G P G R A W Y R T T D I I G D - - I R Q A H C
4102
3 X4 C T R L N N N - K R K R I R I G H I G P G R T I Y A T E G I R G D - - I R Q A H C
2 X4 C T R L S N N - K R K R I R I G H I G P G R T I Y A T E G I K G D - - I R Q A H C
1 R5/X4 C T R P N N N - T R K R I S M - - - G P G R V Y Y T T G E I I G D - - I R R A Y C
1 R5 C T R P N N N - T R K S I P I - - - G P G K A F Y A T G D I I G D - - I R K A Y C
1 R5 C T R P N N N - T R K S I T I - - - G P G K A F F A T G D I I G D - - I R K A Y C
11 R5 C T R L N N N - T R K G I H I - - - G P G G A F Y A R G D I I G D - - I R Q A H C
1233
1 X4 C T R P S K N - V K R M I H I G H I G G G R A W H T T E K I T G N - - L R P - H C
1 X4 C T R P S K S - I K R M I H I G H I G G G R A W H T T E K I T G N - - L R P - H C
1 X4 C T R P D N K M T K R I I H I - - - G P G R A F Y T A K K E - K D F M L R Q A R C
7 R5 C E R P N N N - T R E S V H I - - - G P G R A M F T T - D I I G D - - I R Q A Y C
1924
1 X4 C T R P N N N - I R K S V R I - - - G P G R A F Y T T G K I I G N - - I R Q A H C
1 R5 C T R P N N N - T R K S V P I - - - G P G R A F Y T T G D I I G D - - I R Q A H C
3131
2 R5 C T R P N N N - T R K R I S M - - - G P G R V Y Y T T G E I I G D - - I R K A Y C
1 R5 C T R P N N N - T R K R I S M - - - G P G R V Y Y T T G E I I G D - - I R K A H C
1 R5 C T R P N N N - T R K R I T M - - - G P G R V Y Y T T G E I I G D - - I R R A Y C
3 R5 C T R P N N N - T R R S I S I - - - G P G R A F Y T T G E I I G D - - I R Q A H C
0229
4 R5/X4 C T R P N N N - T R K S I S L - - - G P G R W H - T T E N I I G D - - I R Q A H C
1 R5 C T R P N N N - T R K S I Q L - - - G P G R W H - T T E K I I G D - - I R Q A H C
2 R5 C T R P N N N - T R K S I Q L - - - G P G R W H - T T G E I I G D - - I R Q A H C
1389
6 R5/X4 C T R P N N N - T R K R I S M - - - G P G R V Y Y T T G E I I G D - - I R R A H C
1 R5 C T R P N N N - T R K R I S M - - - G P G R V Y Y T T G E I I G D - - I R K A H C
2327
3 R5/X4 C T R P N N N - T R G R I S I - - - G P G R A F Y A T R D I I G N - - I R Q A H C
1 R5 C T R P N N N - T R G R I S I - - - G P G R A F Y A T R D I I G N - - I R Q A H C
SC
1 R5/X4 C T R L N N N - T R K R I S L - - - G P G R V Y Y T T G Q I V G D - - I R Q A H C
1 R5 C T R L N N N - T R K R I S L - - - G P G R V Y Y T T G Q I V G D - - I R Q A H C
2 R5 C T R P N N N - T R K G V H I - - - G P G K T F Y A T G E I V G D - - I R Q A H C
2 R5 C T R P N N N - T R K G V H M - - - G P G K T F Y A T G E I V G D - - I R Q A H C
1069
1 R5 C T R P N N N - T R K G I H I - - - G P G R R V Y T R E K I I G D - - I R Q A H C
1 R5 C T R P N N N - T S K G I H I - - - G P G R S V Y T R E K I I G D - - I R Q A H C
1 R5 C T R P N N N - T R R G I H I - - - G P G R S V Y T R E K I I G D - - I R Q A H C
1 R5 C T R P N N N - T S K G I H I - - - G P G R S V Y T R E R I I G D - - I R Q A H C
5 R5 C T R P N N N - T S K G I H I - - - G P G R S V Y T R E R I I G D - - I R Q A H C
1486
1 R5 C I R P S N N - T R R G I H L - - - G P G R A L Y T T E K I T G D - - I R Q A H C
1 R5 C T R P S N N - T S K S I T I - - - G P G R A F Y T T E K I I G D - - I R Q A H C
2 R5 C T R P S N N - T S K S I T I - - - G P G R A F Y T T G R I I G D - - I R Q A H C
1 R5 C T R P S N N - T R R G I H L - - - G P G R A L Y T T E R I T G D - - I R Q A H C
1045
3 R5 C S R P G N N - T R K G I H I - - - G P G R G L F Y A G E I V G D - - I R Q A H C
1 R5 C L R P G N N - T S K G I H M - - - G P G R G Y F Y A G R I I G D - - I R K A H C
1 R5 C T R P N N N - T S Q N I R I - - - G P G G A M F R A G R I I G D - - I R E A H C
1 R5 C L R P G N N - T S R G I H M - - - G P G R G Y F Y A G K I I G D - - I R K A H C
1 R5 C L R P G N N - T S - G I H M - - - G P G R G Y F Y A G R I I G D - - I R K A H C
3026
3 R5 C T R L G N N - T R K S I H I - - - G P G R A F F A S Q P I I G D - - I R K A S C
1 R5 C T R L G N N - T S K S I H I - - - G P G R A F F V S Q P I I G D - - I R K A S C





Figure 3.2. V3 loop sequence alignment of X4 and R5 Envs.  
Figure shows the alignment of the predicted amino acid sequence (denoted by single 
letter abbreviation) of phenotypically confirmed X4, R5, and R5/X4 Env V3 loops from 
15 subjects. Columns to the left of the sequence indicate the subject ID, number of Envs 
with the same predicted V3 loop sequence, and the confirmed co-receptor phenotype. 




motif # of subjects Total sequences 
# of sequences 
with co-receptor 
usage available 
GHI 38 234 0 
GI 94 311 0 
	






3.3 X4 Envs have a unique V3 loop protrusion that impacts CCR5 receptor interaction. 
Genetic and structural studies have demonstrated that the Env V3 loop binds the 
chemokine proteins and is the primary viral determinant for co-receptor usage (Deng et 
al., 1996; Dragic et al., 1996; Feng et al., 1996). We hypothesized that the 2 to 3 amino 
acid insertions observed in the X4 Envs influence co-receptor usage. To investigate how 
the insertion modifies the Env V3 loop, we used computational homology modeling 
through the Robetta online server to predict Env structures (Song et al., 2013). One X4 
and one R5 Env sequence was selected from each of the three subjects (1233, 1239, and 
4102) with co-circulating X4 and R5 viruses (Table 3.1). The HIV-1 template chosen by 
the server to predict the structure varied for each subject (Table 3.3). Predicted models 
for each co-circulating X4 and R5 virus pair were then superimposed, which revealed a 
secondary protrusion in all the phenotypically confirmed X4 but not the R5 V3 loop 
Envs. This additional loop coincided with the location of the insertion, either at the tip or 
the base of V3 (Fig 3.3). Subject 1233 contained two different types of insertions, and 
thus, two different X4 sequences were modeled and separate superimpositions were done 
with a co-circulating R5 virus (Fig 3.3c-d). Again, the additional loop aligned with the 
location of the observed insertion. Therefore, this modeling revealed that the predicted 
V3 insertion observed in X4 variants led to an extra protruding structure either at the base 
or the crown of the V3 loop. 
To understand the impact of this protrusion on co-receptor usage, the predicted 
V3 loop structure for subject 4102 was docked with a model of the CCR5 receptor. 




structural model of the receptor. The solved CCR5 structure is in complex with 
Maraviroc, an HIV entry inhibitor, which alters the binding pocket needed for CCR5 – 
Env V3 loop interactions (Tan et al., 2013). This alteration renders the solved CCR5 
structure unusable for understanding interactions with the Env V3 loop. A structural 
model of CCR5 created on a CXCR4 template was produced by Floudas et al., and this 
model was used in the subsequent analysis (Tamamis and Floudas, 2014). Receptor - 
ligand interactions for CCR5 and a 4102 R5 V3 loop Env were predicted using Cluspro 
(Kozakov et al., 2017). The 4102 V3 loop interacted with the second extracellular loop 
(ECL2) and the N-terminal extracellular region (N-term) of CCR5, similar to what has 
been observed using both genetic and biochemical analyses (Brelot et al., 1999; Lee et 
al., 1999; Cormier et al., 2000; Brower et al., 2009). For instance, CCR5 ECL2 amino 
acid Glu283 interacted with crown Env 4102 V3 loop amino acids and Glu18 and Asp11 
in the N-term of CCR5 interacted with base Env V3 loop amino acids as predicted from 
previous work (Fig 3.4a) (Doranz et al., 1997; Dragic et al., 1998; Blanpain et al., 1999; 
Dragic, 2001). Other CCR5 residues important for polar interactions, including Gln4, 
Tyr14, Lys191, Asn258 (Farzan et al., 1998; Rabut et al., 1998; Kuhmann et al., 2000; 
Navenot et al., 2001; Maeda et al., 2006; Napier et al., 2007), were found to make 
interactions with the V3 loop (Table 3.4, Fig 3.5).  
Docking studies of CCR5 and the predicted X4 V3 loop did not generate a usable 
model. All predictions put the X4 V3 loop in orientations that did not interact with the 
CCR5 receptor. In order to predict the interaction between CCR5 and an X4 V3 loop, the 




complex (Fig 3.4a). The R5-utilizing V3 loop was then removed so that the interactions 
of CCR5 -X4 V3 loop could be observed. This model revealed that the X4 Env V3 loop 
crown, specifically the amino acid insertions, clashed with Met279 and Glu280 in the 
CCR5 ECL2 (Fig 3.4b). The predicted V3 loop of subject 1233 with the insertions at the 
base of the loop was also superimposed on the R5 V3 loop of subject 4102 to model 
CCR5 interactions. Neither of the 2 base insertions appeared to clash with CCR5 in this 
model (Fig 3.4c). However, the base of the V3 loop appears to spill out of the CCR5 
binding pocket in a fashion that was not observed with subject 4102 (Fig 3.4a). Indeed, 
V3 loop interactions with the CCR5 N-term amino acids Glu18 and Asp11 were not 
observed (Fig 3.4c). Together, these structural modeling data suggests that steric 
hindrance prevents exclusively CXCR4-using Envs from interacting with the CCR5 
protein when insertions are present at the crown of the V3 loop. On the other hand, 
insertions at the base, observed in some X4 V3 loops, eliminate important interactions 
with amino acids in the CCR5 N-terminal region. Thus, this structural model provides 
insight on how observed modifications in the V3 loop Env prevent utilization of the 








Figure 3.3. Structural modeling of co-circulating X4 and R5 V3 loops.  
Figures A-D depict X4 (blue) and R5 (red) V3 loops aligned and superimposed onto each 
other for each subject. Location of predicted V3 loop insertions is depicted in green. 
Subject 1233 had Envs with insertions before the crown and one Env with insertions near 


























Figure 3.4. X4 V3 loop interactions with CCR5 receptor.  
(A) The interaction between CCR5 (light blue) and 4102-R5 V3 loop (red) was modeled 
by Cluspro protein: protein docking server. Figure shows the previously described 
specific interactions between the V3 loop and CCR5 receptor. Hydrogen bonds are 
depicted as black dashes. Specific individual amino acids are denoted in black. 
Interactions are depicted with stick configurations. (B) Superimposition of 4102-X4 V3 
loop (blue) on the predicted 4102-R5 V3 loop – CCR5 (light blue) model. Predicted 
steric clash at positions 279 and 280 are highlighted in cyan. Stick configuration at the tip 
of the V3 loop shows the three-amino acid insertion (green) observed in X4 Envs. (C) 
Interaction of 1233-X4 V3 loop (blue) with insertions at the base interacting with the 
CCR5 receptor (light blue). Stick configuration shows the amino acid insertions (green) 




dashes represent interactions that were expected to be made between the V3 loop and 
CCR5 based on the interaction of 4102-R5 V3 loop and CCR5 interaction.  
 
Virus Template (PDB #) 
4102-X4 5fykG_203                                         
4102-R5 5fykG_203                                         
1239-X4 5fykG_203                                         
1239-R5 5fykG_203 
1233-X4(crown insertion) 5fuuE_203 
1233-X4(base insertion) 3j70D_201 
1233-R5 5fykG_203 
 
Table 3.3. Templates for homology modeling of X4 and R5 gp120 selected by 
Robetta  
 



























Figure 3.5. CCR5 interactions with 4102 R5 V3 loop.  
Figure depicts the hydrogen bond interactions between CCR5 (light blue) and 4102-R5-
using V3 loop (red). Hydrogen bonds are depicted as black dashes. CCR5 residues of 






3.4 X4 as compared to R5 viruses are less neutralization sensitive.  
We hypothesized that humoral immune responses select for the significant 
sequence and structural differences observed between X4 and R5 Envs. The HIV-1 V3 
loop is a target for host neutralizing antibodies (Hartley et al., 2005; Zolla-Pazner, 2005), 
and HIV readily evades this immune response (Richman et al., 2003; Wei et al., 2003; 
Moore et al., 2009; Rong et al., 2009). Neutralization susceptibility was compared among 
co-circulating X4 and R5 viruses in 3 subjects (4102, 1239, and 1233) (Table 3.1). 
Neutralization differences were first assessed against contemporaneously collected 
autologous plasma because decreased susceptibility would directly suggest escape from 
host generated humoral responses. A median of three (range 1 - 5) X4 viruses were 
compared to five R5 variants in each individual. Maximum likelihood trees showed that 
all R5 and X4 Envs from each sample clustered separately (Fig 3.6), and thus all 
examined viruses were genetically distinct from one another. Neutralization sensitivity 
was estimated using AUC. While IC50 is generally used as a measure of neutralization 
susceptibility, AUC allows comparisons both over the entire range of inhibitor 
concentrations and in instances where greater than 50% inhibition is not achieved at the 
highest tested dilution (Yu et al., 2012). The AUC varies from 0 signifying no 
neutralization to 1 representing 100% inhibition. AUC was used rather than IC50 because 
50% inhibition was not observed at the highest contemporaneous autologous plasma 
dilution (1:50) in a number of cases, especially against the X4 strains. In all 3 individuals, 
the median AUC was lower for the X4 as compared to R5 viruses, implying that they 




Each individual’s median AUC for the X4 and the R5 variants was also compared, and 
this aggregate analysis revealed that the CXCR4- (median AUC= 0.192; range= 0.173-
0.272) had more than 2-fold lower inhibition AUC as compared to the co-circulating 
CCR5- (median AUC= 0.414; range= 0.407-0.458) (p=0.100, Mann Whitney test) using 
variants (Fig 3.7d). As detailed below in the correlation analysis between IC50 and AUC, 
this greater than 2-fold variation in AUC corresponds to more than 3-fold IC50 difference. 
Previous study has noted similar IC50 fold changes among longitudinally collected 
viruses to sequentially collected autologous plasma suggesting that the observed changes 
are biologically meaningful (Richman et al., 2003). Thus, decreased sensitivity to 
contemporaneous autologous antibodies suggests that X4 viruses are neutralization 
escape variants. 
Neutralization comparisons to autologous contemporaneous plasma were limited 
because we were only able to identify 3 individuals that had co-circulating R5 and X4 
strains (Table 3.1). To further investigate if X4 viruses arise as neutralization escape 
variants, we tested neutralization sensitivity of X4 and R5 variants to heterologous 
pooled plasma. The heterologous pooled plasma was from 10 individuals that were 
confirmed by both bulk genotype and bulk Env pseudovirion phenotypic assays to 
contain no CXCR4-using viruses (Henrich et al., 2014). We reasoned that this 
heterologous pooled plasma constituted a standard that could be used to compare 
neutralization susceptibility differences between X4 and R5 Envs. Importantly, none of 
the X4 and R5 Envs was obtained from plasma used to constitute the heterologous pool. 




from autologous humoral responses. We examined one randomly selected X4 variant 
from each of the six individuals with X4 viruses (Table 3.1). Neutralization susceptibility 
of these six X4 Envs was compared to one randomly selected R5 virus from the 
remaining 9 subjects detailed in Table 3.1. Thus, in this comparison, all viruses were 
from different individuals. Estimated IC50 was more than 3-fold lower for X4 (median 
IC50= 32.8; range= 25 -189) as compared to R5 (median IC50= 108; range= 67.4 - 515) 
variants (p = 0.021, Mann Whitney test) (Fig 3.8a). X4 (median AUC= 0.195; range 
AUC=0 - 0.370) as compared to R5 (median AUC=0.357; range AUC=0.312 - 0.579) 
using viruses also demonstrated nearly 2-fold lower inhibition AUC to pooled 
heterologous plasma (p=0.049, Mann Whitney test) (Fig 3.8b). As expected, IC50 directly 
correlated with AUC (spearman r= 0.872; p=0.0002) (Fig 3.8c). Thus, in general, X4 as 











































Figure 3.6. Maximum likelihood (ML) tree analysis of co-circulating X4- and R5- 
utilizing Env sequences. 
 Co-circulating X4- and R5- utilizing Env gp120 sequences from 3 dual mixed samples, 
(A)4102, (B)1239, and (C)1233 were aligned with reference sequence NL4-3 using Los 
Alamos HIValign. ML trees were generated using PhyML with default settings. 





Figure 3.7. Neutralization sensitivity of co-circulating X4 and R5 viruses.  
Neutralization sensitivity depicted as AUC (y-axis) for R5 (red) and X4 (blue) viruses for 
subject (A) 4102 (B) 1239, (C) 1233 against contemporaneously collected autologous 
plasma. Each point denotes a unique Env and is the mean from duplicate independent 
experiments. (D) Aggregate comparisons were computed for subjects, 4102 (green), 1233 
(orange), and 1239 (red), and each point represents the median AUC value within a 
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Figure 3.8. Neutralization sensitivity differences among X4 and R5 viruses.  
(A) Neutralization sensitivity, depicted as IC50 (y-axis), for 6 X4 (blue) and 9 R5 (red) 
viruses against a heterologous plasma pool. IC50 is the reciprocal of the plasma dilution 
showing 50% inhibition. For statistical comparisons, a value of 25 (midpoint between 0 
and 50) was assigned when the 50% neutralization was not achieved at the highest tested 
plasma dilution (1:50). (B) Neutralization sensitivity for 6 X4 (blue) and 9 R5 (red) 






calculated for neutralization experiments that reached 50% inhibition (11 viruses) and 
plotted against each other. Four virus/plasma combinations in which greater than 50% 
inhibition was not observed at the highest tested plasma dilution were not included in this 
correlation analysis. In all graphs, each point represents the average of duplicate 
independent neutralization assays. In each graph, the box plot denotes median and 





3.5 Individuals with DM as compared to strictly R5 viruses have similar neutralization 
fingerprints, breadth, and potency.  
In contrast to our observations, prior studies have found that X4 Envs are more 
sensitive to sera and neutralizing antibodies (nAbs) (Cecilia et al., 1998; Montefiori et al., 
1998; Trkola et al., 1998; Bunnik et al., 2007). From these observations, it has been 
argued that CXCR4-using variants arise only in the absence of a strong humoral 
response, suggesting that individuals with DM as compared to R5 only virus populations 
should have different neutralization profiles (Ho et al., 2007). We compared 
neutralization breadth and potency among plasma samples collected from individuals 
with documented DM versus R5 only viruses to assess if individuals that harbor CXCR4-
using viruses have poorer antibody responses. Neutralization capacity was examined 
against a reference global Env panel, consisting of 12 R5 viruses of varying subtypes. 
Observed neutralization responses against these 12 Envs are reflective of neutralizing 
breadth and potency against a larger panel of 219 viruses (deCamp et al., 2014). Only 11 
viruses were used in this study, however, because we were unable to generate a 
replication competent virus with 1 of the 12 Envs in this reference panel (Ghulam-Smith 
et al., 2017). We compared neutralization responses among plasma from 8 and 10 
individuals with documented DM and R5 only virus populations, respectively. DM 
(median= 109 cells/mm3; range= 5-390) and R5 only (median= 152 cells/mm3; range= 7-
719) individuals did not have a significantly different CD4 count (p=0.762, Mann 




copies/mL, R5- median= 244,160; range= 20,395-1,745,056) (p=0.068, Mann Whitney 
test) (Fig 3.9).  
  DM and R5 only plasma had no significant difference in their neutralization 
profile because heat maps revealed that the individuals from the 2 groups were 
intermingled (Fig 3.10a). Plasma neutralization breadth and potency were estimated using 
a previously defined Breadth and Potency (BP) score (Ghulam-Smith et al., 2017). 
Briefly, BP score consisted of the average log normalized percent neutralization at the 
highest tested plasma dilution (1:50) across all the viruses in a panel. Importantly, we 
have previously shown that this BP score accurately differentiates antibodies with 
varying breadth and potency (Ghulam-Smith et al., 2017). DM (median BP score= 0.565; 
range= 0.333 - 0.921) and R5 (median BP score= 0.518; range= 0.285 - 0.790) plasma 
did not have a significantly different BP score (p =0.515) (Fig 3.10b). Furthermore, DM 
(median breadth=45.45%; range=0 - 100%) and R5 only plasma (median 
breadth=31.82%; range=0-81.82%) did not have significant difference in neutralization 
breadth, which was defined as the percent of Envs in the panel neutralized at greater than 
50% at the highest tested plasma dilution (Fig 3.10c). Interestingly, plasma from the 3 
individuals (1233, 1239, and 4102) with co-circulating X4 and R5 viruses were among 
the top neutralizers, neutralizing at least 9 of 11 viruses by at least 50% at the highest 
tested plasma dilution.  
Neutralization capacity was also examined against another Env collection consisting of 2 
R5X4 and 3 X4 viruses because CXCR4-using variants are not included in the global 




NL4-3, and 4 other primary isolates, including a subtype C Env with previously 
phenotypically characterized receptor usage (Lin et al., 2016). The heat map 
demonstrated that the DM and R5-only plasma samples were intermingled, which 
suggests that the 2 groups also have similar neutralization fingerprints against this 
CXCR4-using Env collection (Fig 3.10d). DM (median=0.3215; range=0.102-.907) and 
R5 only (median=0.367; range=0.231-0.687) plasma had no significant difference in BP 
score (p=0.697, Mann Whitney test) (Fig 3.10e). DM (median=0%; range=0-100%) and 
R5 only (median=10%; range=0-80%) plasma also had no significant difference in 
neutralization breadth (p=0.844, Mann Whitney test) (Fig 3.10f). Interestingly, 2 of the 3 
individuals (4102 and 1233) with the highest BP score against the global reference Env 
panel also had greatest ability to neutralize Envs in the CXCR4-using virus collection. 
For instance, DM subject 4102 was the top neutralizer for both panels, demonstrating 
over 90% neutralization against 9 of a combined 16 viruses from both panels and over 
50% neutralization against the entire global panel and all CXCR4-using collection 
viruses (Fig 3.10a, d).  
Neutralization susceptibility of the Envs in the reference global panel was further 
compared to those in the CXCR4-using collection. The DM and R5 only plasma had 
significantly lower BP score against the CXCR4-using (median= 0.338; range= 0.102- 
0.907) as compared to the global reference Env (median= 0.472; range= 0.318- 0.926) 
panel (p=0.017, Wilcoxon matched-pairs test) (Fig 3.10g). Furthermore, neutralization 
breadth was significantly lower against the CXCR4-using (median= 0; range= 0-100) as 




0.025, paired Wilcoxon matched-pairs test) (Fig 3.10h). Similar to the heterologous 
pooled plasma data (Fig 3.8a-b), these observations confirm that CXCR-using as 























Figure 3.9. Absolute CD4 count and virus level among dual mixed (DM) plasma and 
plasma with only CCR5 using viruses.  
(A) Absolute CD4 count (cells/mm3) and (B) HIV RNA viral load log (copies/mL) for 8 
DM (circles) and 10 CCR5 only (squares). Differences were not statistically different (p 
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Figure 3.10. Breadth and potency of DM 
and CCR5 only plasma samples.  
(A, D) Figures depict neutralization heat maps for plasma from 8 DM subjects (blue) and 




panel viruses (D) 5 CXCR4-using variants (x-axis). Color Key Histogram represents the 
distribution of neutralization across all subjects. Yellow shade represents 0-49% 
neutralization, light orange represents 50-69% neutralization, orange represents 70-89% 
neutralization, and red represents 90-100% neutralization. Viral subtypes of the Envs in 
the panel are depicted as colors on the x-axis: A (khaki), B (gray), C (teal), G (green), AC 
(pink), CRF01_AE (forest green), and CRF07_BC (purple). (B, E) Breadth and potency 
(BP) score for DM (circle) and CCR5 only plasma (square) against the global Env panel 
(B) and against a collection of CXCR4-using viruses (E). BP score ranges from 0 – 1 
with 0 and 1 denoting no and 100% neutralization respectively. (C, F) Breadth (% of 
Envs neutralized at greater than 50% at the highest tested plasma dilution) observed for 
the DM (circle) and CCR5 only plasma (square) against the global (C) and CXCR4-using 
(F) Env panel. (G) BP score of the plasma samples against the global as compared to the 
CXCR4-using Env panel. (H) Breadth of the plasma samples against the global as 
compared to the CXCR4-using Env panel. In all cases, each point represents one plasma 
sample and values are a mean from a minimum of 2 independent assays. In each graph, 
the box plot denotes median and interquartile range. Star denotes statistically significant 






We have analyzed genotypic, structural, and neutralization differences between 
X4 and R5 Envs. Comparison of co-circulating viral sequences reveals a 2 to 3 amino 
acid insertion in the X4 V3 loops that has not been previously described for HIV-1B (Fig 
3.2). Structural modeling of X4 and R5 Envs suggest that these insertions result in an 
additional protrusion within the V3 loop (Fig 3.3). Modeling of the X4 V3 loop with the 
CCR5 chemokine receptor predicts that this additional protrusion impacts docking (Fig 
3.4). Neutralization sensitivity studies revealed that X4 as compared to co-circulating R5 
viruses are less neutralization sensitive to autologous plasma (Fig 3.7). In addition, 
CXCR4-using as compared to R5 variants are more neutralization resistant to both pooled 
heterologous plasma (Fig 3.8) and plasma from diverse individuals (Fig 3.10). 
Furthermore, neutralization assessments showed that plasma from individuals with 
confirmed DM and R5 only virus populations had similar neutralization profiles (Fig 
3.10). In aggregate, these observations show that X4 as compared to R5 variants are more 
neutralization resistant, suggesting they arise as neutralization escape variants. These 
conclusions have implications for future antibody based HIV-1 therapeutics. 
The 2 to 3 amino acid V3 loop insertion falls in the same two general regions, 
either directly before the GPG crown or towards the base of the V3 loop. V3 loop 
insertions have been shown in other non-subtype B HIV-1 and SHIV. In these settings, 
the insertions have also been associated with exclusive CXCR4 usage (Feng et al., 2002; 
Tasca et al., 2008; Lin et al., 2012; Zhang et al., 2014). A search for the GHI or GI 




revealed multiple subtype B Envs bearing this signature. However, co-receptor usage was 
not defined for any of these variants. This genotypic analysis suggests that the identified 
V3 loop insertions have perfect specificity for predicting X4 variants. While these 
insertions are highly predictive for X4 viruses, not all CXCR4-using Envs, such as the 
R5X4 variants and Env from subject 1924, contain this feature. Thus, this genotypic 
signature cannot be used as a tool for both excluding CXCR4-usage and determining the 
appropriateness of CCR5 inhibitors as potential therapy (Rao, 2009; Gilliam et al., 2011).  
Our modeling data showed that the unique insertions observed in X4 variant V3 
loops had structural consequences. Structural modeling demonstrated that X4 as 
compared to R5 V3 loops had additional V3 protrusions, which directly corresponded 
with the observed sequence insertions. To our knowledge, no previous study has 
demonstrated this stark structural difference between co-circulating HIV-1 Envs. The V3 
loop – CCR5 docking modeling further implied that the protrusion led to steric hindrance 
because the crown of the V3 loop clashed with amino acids in the CCR5 receptor ECL2. 
On the other hand, the protrusion at the base of the X4 V3 loop eliminated important 
interactions with amino acids in the CCR5 N terminal region. Structural predictions that 
incorporate an Env trimer or an entire monomer surface unit may reveal further structural 
constraints that are not evident in the partial V3 loop only model. Prior studies have 
found differences in charge (Yokoyama et al., 2012; Chandramouli et al., 2013), 
hydrogen-bond donor sites and aliphatic side chain orientation (Sander et al., 2007), and 
hydrophobicity (Bozek et al., 2013) as potential explanations for co-receptor specificity. 




the V3 loop sequence. Thus, our modeling provides a rational mechanistic understanding 
for the loss of CCR5 receptor usage among some exclusive CXCR4-using Envs.  
Forces promoting V3 insertions and structural protrusions remain unclear. We show that 
X4 as compared to co-circulating R5 strains were more neutralization resistant to 
autologous plasma. Furthermore, CXCR4-using variants are less susceptible to 
heterologous pooled plasma and plasma from diverse HIV-1 infected individuals as 
compared to the R5 strains. This strongly argues that the V3 insertions do not arise due to 
chance alone because random mutations should not lead to a shared genotypic and 
phenotypic characteristic. Our data argues that humoral immune pressure selects for X4 
variants and the exclusive CXCR4-utilizing strains are escape mutants. Prior studies, 
however, have implied that CXCR4-utilizing viruses only arise after humoral responses 
wane (Bunnik et al., 2007; Ho et al., 2007). The waning humoral immunity model would 
predict that individuals with CXCR4-using as compared to those with only R5 viruses 
would have decreased anti-HIV-1 neutralization capacity or unique neutralization 
fingerprints. We, however, showed that individuals who have a mixture of CXCR4- and 
CCR5-utilizing viruses as compared to those that only have R5 strains have similar anti-
HIV-1 neutralization fingerprints. In aggregate, our observations argue that X4 variants 
emerge as a consequence of and not due to the lack of humoral immunity. Indeed, we 
have previously demonstrated that CXCR4-using variants can emerge over time while 
being passaged in the presence of increasing concentrations of autologous plasma (Lin et 
al., 2016). Another recent investigation has further shown that CXCR4- and CCR5- using 




neutralization escape enhances susceptibility to the various IFITMs, but we and others 
have demonstrated that during the later stages of disease, when CXCR4-using viruses 
generally emerge, Envs become less sensitive to interferon responses (Fenton-May et al., 
2013; Etemad et al., 2014; Foster et al., 2016). Collectively, these findings argue that 
CXCR4-using viruses may emerge to escape both antibody and innate interferon 
pressure.  
Humoral immunity could select for X4 strains because the observed V3 insertions 
potentially disrupt known antibody epitopes (Cormier and Dragic, 2002; Garces et al., 
2014; Caskey et al., 2017). For instance, the insertions would modify binding of 
previously isolated V3 directed antibodies that bind at the crown or the base of the V3 
loop (Gorny et al., 1993). Besides these types of antibodies, bnAbs that depend on the 
asparagine (N) 332 supersite, located in close proximity to the V3 loop, for activity may 
also select for CXCR4-using viruses. Indeed, HIV-1 infected humanized mice treated 
with an anti-V3 loop directed bnAb, PGT128, had a higher predicted frequency of 
CXCR4-using variants as compared to mice treated with an anti-CD4 binding site bnAb, 
45-46GW, suggesting antibody mediated selection (Pfeifer et al., 2014). While the anti-
V3 loop class of bnAbs are directed to the N332 - linked glycan at the base of the V3 
loop, they have also been shown to interact with other V3 loop amino acids. For instance, 
anti-V3 loop bnAb, PGT121, interacts with residues at the tip of the V3 loop including 
the GPG crown and amino acids directly before and after it (Cormier and Dragic, 2002). 
Another anti-V3 loop bnAb, 10-1074, interacts with residues towards the base of the V3 




regions in which insertions were observed. In aggregate, this implicates antibody pressure 
as a reasonable selective force for the insertions and exclusive CXCR4-usage. Isolating 
antibodies from individuals that harbor X4 strains with V3 loop insertions will provide 
more definitive proof for this notion. It is quite possible that R5X4 strains and X4 
variants that lack V3 loop insertions arise by other mechanisms, and our proposed model 
is not mutually exclusive from other hypotheses for co-receptor switching.  
We also assessed neutralization breadth and potency against two separate Env 
collections, the global reference and the CXCR4-using panel. We found that, in general, 
plasma samples displayed decreased ability to neutralize Envs in the CXCR4-using as 
compared to the global reference panel. The global reference Env collection has been 
proposed as a standardized panel to evaluate neutralization capacity (deCamp et al., 
2014). This panel, however, contains no CXCR4-utilizing viruses. Our results argue that 
CXCR4-using, especially X4 strains, should be included in a standardized Env collection 
for a more accurate assessment of plasma or antibody breadth and potency. 
This study had several limitations. First, longitudinal samples were not available. 
Demonstrating that viruses isolated before and after co-receptor switching have different 
neutralization susceptibility, especially to autologous plasma, would provide more 
definitive evidence for humoral selection driving the emergence of CXCR4-usage. 
Longitudinal sampling, however, was not possible because enrollees in this trial initiated 
cART relatively soon after initial blood donation, and co-receptor switching would be 
unlikely to occur with suppression of virus replication (Gulick et al., 2004). Another 




3 individuals and a relatively small number of co-circulating strains per subject. Even 
though we amplified over 900 Envs using SGA, we had difficulty identifying individuals 
that harbored a mixture of X4 and R5 strains. Even with the small sample size and cross-
sectional sampling, X4 as compared to R5 viruses were consistently less neutralization 
sensitive to both autologous and heterologous plasma. This strongly argues that 
neutralization escape is linked with the unique genotypic and structural features observed 

















CHAPTER FOUR: HIV-1 Co-Receptor Usage Impacts Sensitivity to V1-V3 Loop 
Broadly Neutralizing Antibodies 
Background 
The discovery of HIV-1 broadly neutralizing antibodies has provided a new 
framework for HIV vaccine design. The ability of these antibodies to neutralize 
numerous HIV-1 strains gives promise that individuals could generate similar types of 
antibodies against vaccine immunogens (Burton and Hangartner, 2016). In addition, 
bnAbs have opened a new arena for therapeutics against HIV-1(Bhiman and Lynch, 
2017). The latest generation of bnAbs not only have great breadth but higher potency as 
compared to previous antibodies (McCoy and Burton, 2017). In addition, bnAb 
engineering allows for even greater potency, breadth, and half-life, making them an 
attractive alternative to once a day ARV (Hinton et al., 2006; Sievers et al., 2015). 
Indeed, multiple bnAb are already in various stages of clinical trials for use as 
therapeutics. To date, seven studies using monotherapy of VRC01, 3BNC117, and 10-
1074 have been completed in healthy or chronically infected individuals (Scheid et al., 
2011; Caskey et al., 2015; Ledgerwood et al., 2015; Lynch et al., 2015; Scheid et al., 
2016; Schoofs et al., 2016; Caskey et al., 2017). Although, only transient suppression or 
reduction in viremia was achieved in all studies, they demonstrate the safety and viability 
of bnAbs as a treatment option. As a result of these studies, several shortcomings were 
highlighted and must be addressed before bnAbs can enter the clinical sphere. First, 
monotherapy often lead to resistance or decreased sensitivity to the virus. It is expected 




Lynch, 2017). Second, several subjects carried pre-treatment resistant strains to the tested 
bnAb (Lynch et al., 2015; Caskey et al., 2017). Treatment was ineffective in these 
individuals. A tool to decipher neutralization susceptibility to bnAbs before the start of 
therapy is needed.  
For all ARVs, susceptibility is tested prior to the start of any drug cocktail using 
either a genotype or phenotype based assay (Arts and Hazuda, 2012). BnAbs will 
undoubtedly be an expensive therapy option, therefore, it will be imperative to evaluate 
bnAb susceptibility prior to the start of treatment as well. While modifications to the 
antibody epitope, such as the absence of asparagine (N) linked glycosylation at amino 
acid 332 and 160 (termed N332 and N160), can predict resistance to V3 and V1-V2 
directed bnAbs, respectively, other Env changes can also cause bnAb resistance. Indeed, 
in both NHP and human trials, multiple resistant variants emerged with intact epitopes 
(Barouch et al., 2013; Shingai et al., 2014; Caskey et al., 2015; Caskey et al., 2017). Env 
is highly diverse and, thus genotype assays alone are unlikely to predict susceptibility for 
these types of resistant variants. Currently, the alternative is to isolate individual 
envelopes, generate viruses that incorporate these envelopes and perform neutralization 
experiments. These assays are expensive, time-consuming, and labor intensive. In the 
clinical sphere, a more rapid and cost-effective method is needed. In this study, we 
present data suggesting that structural modeling of the HIV-1 Env with bnAbs can serve a 
tool to investigate neutralization susceptibility. 
One viral phenotype that may partially predict susceptibility to some bnAbs is co-




resistance to PG9 and PG16 (Pfeifer et al., 2014). Previous work published by our lab 
also found a difference in neutralization sensitivity between X4- and R5-using viruses 
against heterologous and autologous antibodies (Lin et al., 2016). Even though certain 
bnAb classes target Env regions known to be important for co-receptor usage, very few 
studies have examined the association between co-receptor utilization and neutralization 
sensitivity. In this study, we also examine the role of co-receptor usage on neutralization 
sensitivity to various bnAbs.  
Results 
4.1 Subjects and sequences. 
The subjects and viruses selected for analysis in chapter 3 were further analyzed 
in this study (Table 3.1). We selected the highest titer X4 virus from the 6 samples 
containing X4 viruses and the highest titer R5 virus from 8 samples for examination. 
Virus from subject 1389 was not used in this study because only a limited quantity of 
virus was available. Co-circulating X4 and R5 viruses from subjects 4102, 1239, and 
1233 were also examined further (Table 3.1).  
4.2 Area under the curve correlates with IC50 values.  
 
Neutralization assays are widely used to assess neutralization sensitivity of 
viruses to antibodies. Half maximal inhibitory concentration (IC50), the minimum 
concentration needed to reach 50% inhibition, is currently the standard used to quantify 
neutralization. Recently, however, AUC values have also been used with a varying 




dilution data from a neutralization assay, allowing a wider range of points to be 
considered, as opposed to only assessing differences around the 50% inhibition point (Yu 
et al., 2012). Despite the potential benefits of using the AUC method, no correlation has 
been established between the estimates from the two approaches for assessing bnAb 
neutralization. In order to compare AUC with IC50, we performed neutralization assays 
with multiple bnAbs against a panel of viruses and then quantified neutralization 
sensitivity using both methods. A total of 14 viruses were tested against 6 bnAbs 
spanning epitopes throughout the HIV-1 Env. Neutralizations that failed to reach 50% 
inhibition were excluded in the correlation analysis because IC50 could not be calculated 
in these instances. We found a significant correlation between AUC and IC50 for all six 
antibodies tested (spearman r range: -0.818- -0.979; p-value <0.0001-0.0033) (Fig 4.1a-
f). These data suggest that AUC is a viable and accurate method for measuring 













































Figure 4.1. AUC values correlate with IC50 values.  
Graphs show IC50 and AUC values for 14 independent primary envelopes against (A)10-
1074 (B)PGT121 (C)PG9 (D)PG16 (E)VRC01 and (F)10E8. (A, B) Six (C, D) seven and 
(E) three virus/plasma combinations in which greater than 50% inhibition was not 
observed at the highest tested plasma dilution were not included in this correlation 
analysis. In all graphs, each point represents the average of duplicate independent 







4.3 X4 utilizing viruses are less neutralization sensitive to anti-V3 loop antibodies as 
compared to heterologous R5 utilizing viruses.  
HIV diversity presents a major challenge for therapeutics and vaccine 
development. An antibody based treatment must be capable of neutralizing virus across 
clade and co-receptor usage. BnAbs have been shown to neutralize viruses across clades, 
however, the association between co-receptor usage and neutralization susceptibility has 
not been examined. To examine the association between co-receptor usage and bnAbs, 
we assessed the susceptibility of 8 R5 and 6 X4 viruses (Table 3.1) to various bnAbs. 
Neutralization sensitivity was assessed against 2 anti-V3 loop antibodies, PGT121 and 
10-1074, 2 anti-V1/V2 antibodies, PG9 and PG16, an anti-CD4 binding site, VRC01, and 
an anti-gp41 membrane-proximal external region (MPER) antibody, 10E8. X4 viruses 
(median AUC=0.071, range= 0.0-0.857) as compared to R5 viruses (median AUC=.589, 
range=0.173-0.986) were around 5-fold less sensitive to V3 directed antibodies PGT121 
(p = 0.033, Mann Whitney test) (Fig 4.2a). Similarly, X4 viruses (median AUC=0.225, 
range=0.0-0.782) as compared to R5 viruses (median AUC=0.830, range= 0.0-0.972) 
were around 3-fold less sensitive to V3 directed antibody 10-1074, although the 
difference was not statistically significant (p=0.0601, Mann Whitney test) (Fig 4.2b). X4 
viruses were at least two-fold less neutralization sensitive to V1/V2 loop directed 
antibodies, PG9 (median AUC= 0.31268, range=0.0-.974) and PG16 (median 
AUC=0.349, range=0.127-0.984), as compared to R5 viruses (median AUC= 0.787 and 
0.796, range= 0.086-0.867 and 0.216-0.986) respectively, although these differences were 




Mann Whitney test, respectively) (Fig 4.2c-d). These neutralization differences were 
restricted to regions involved in co-receptor usage. We did not observe neutralization 
differences to bnAbs against the CD4-binding site and MPER (Fig 4.2e-f). Thus, this data 
suggests that co-receptor usage effects neutralization sensitivity to antibodies targeting 






























Figure 4.2. X4-using viruses are less neutralization sensitive to V1/V2 and V3 loop 
bnAbs as compared to R5-using viruses.  
(A-F) Each graph depicts neutralization sensitivity as AUC values (y-axis) for R5 (blue 
squares) and X4 (red circles) viruses against (A) PGT121, (B) 10-1074, (C) PG16, (D) 
PG9, (E) VRC01, (F) 10E8. AUC values range from 0-1, 0 representing 0% 
neutralization and 1 presenting 100% neutralization. Each point represents the average of 




4.4 Structural model reveals orientation of V1/V2 loop can dictate sensitivity to V3 loop- 
directed antibodies.  
V3 loop directed antibodies PGT121 and 10-1074 bind an N-glycan at position 
332, however, each antibody also interacts with residues within the V3 loop. PGT121 
interacts with residues in the tip of the V3 loop directly before the GPG crown, while 10-
1074 is reliant on successful interaction with the DIRAQ motif near the base of the V3 
loop. These residues, interestingly, coincide with the two regions where insertions were 
observed in the isolated X4 viruses. Subject 4102 had viruses with insertions at the tip of 
the V3 loop which correspond to the PGT121 epitope and subject 1233 had one X4 virus 
that had insertions at the base of the loop in the DIRAQ motif important for 10-1074. To 
further understand the role of these insertions on antibody susceptibility, we analyzed 
neutralization of co-circulating X4 and R5 viruses. Neutralization was tested against 
PGT121 and 10-1074 for both subjects. The 4102 X4 viruses (median AUC= 0.359) 
harboring changes near the crown deemed important for PGT121 activity were less 
neutralization sensitive to PGT121, compared to the R5 viruses (median AUC= 0.605), 
although the difference was not statistically significant (p= 0.155, Mann Whitney test) 
(Fig 4.3a). In contrast, the 4102 X4 and R5 viruses, which had no consistent difference in 
the 10-1074 V3 epitope, had relatively similar sensitivity to 10-1074 (AUC= 0.335-
0.901) (Fig 4.3b). 1233 viruses were not well neutralized by 10-1074, however, a 
neutralization difference was still observed, although again it was not significant (p= 
0.142, Mann Whitney test). On the other hand, the 1233 X4 viruses (median AUC= 




0.315), although the difference was not statistically significant (p = 0.149). Importantly, 
the one X4 virus with the insertion at the base was completely resistant to the 10-1074 
bnAb (Fig 4.3b). PGT121 did not neutralize both R5 or X4 viruses from subject 1233 and 
thus the impact of changes observed around the V3 crown on susceptibility to PGT121 
could not be assessed (Fig 4.3a). In order to visualize how these changes in the V3 loop 
effected binding to the antibody, structural modeling was done.  
The full-length Env sequence of two 4102 viruses, one CCR5-using virus 
sensitive to PGT121 (4102-68) and one exclusively CXCR4-using virus that was resistant 
(4102-3_6), were aligned. Viruses were described as resistant to an antibody if 35% 
neutralization was not reached at the highest concentration tested. The alignment revealed 
multiple changes in V1/V2 and V3 loops, and thus, no obvious genotypic changes could 
be used to explain the difference in neutralization sensitivity in observed between 4102 
co-circulating X4 and R5 viruses’ other than the described insertions (Fig 4.4a). The N-
glycan site at position 160 necessary for binding of V1/V2 loop directed antibodies were 
intact for both viruses. The N332 site important for anti-V3 loop antibody binding was 
present in both viruses, as well. Multiple other differences were observed between co-
circulating viruses that may explain neutralization sensitivity differences between viruses 
with intact antibody primary binding epitopes. In order to visualize how V3 loop changes 
affect neutralization sensitivity, we used an online homology modeling server, Robetta, to 
predict the structure of the Env gp120 unit for several 4102 viruses. The template 
selected by Robetta to predict each Env was the crystal structure of a fully glycosylated 




and VRC01 (PDB ID 5FYKG) (Stewart-Jones et al., 2016). To visualize the predicted 
Envs in complex with PGT121, 4102-68 and 4102-3_6 models were aligned to BG505 
SOSIP.664 structure in complex with the fab region of a precursor to the PGT121 family 
of antibodies, 3H+109L (PDB ID 5CEZ) (Garces et al., 2015). Although PGT121 in 
complex with a gp120 subunit would be the ideal complex to model the interaction 
between our Env models and the bnAb, only precursor Fab regions have been 
experimentally solved in complex with gp120. This PGT121 Fab precursor, 3H+109L, 
however, showed high similarity to PGT121 (PDB ID 4FQ1) across the entire fab as 
measured by root-mean-square-deviation (RMSD=3.054). RMSD measures the average 
distance between atoms in the backbone of superimposed proteins. Two similar structures 
have low RMSD, close to zero. In addition, the angle of approach of the antibody to 
GP120 was conserved (Fig 4.5). Together, this suggests that 3H+109L was a suitable 
structure to model the interactions of our predicted models with PGT121. The 
superimposition of 3H+109L:GP120 with Env models 4102-68 and 4102-3_6 revealed 
that the orientation of V1/V2 loop differed between the two Envs (Fig 4.4b). 4102-68, the 
R5-using sensitive virus, had a V1/V2 loop that pointed away from the PGT121 
precursor, whereas 4102-3_6, the X4-using resistant virus, pointed directly at the 
PGT121 precursor Fab. This orientation causes a clash with the antibody, revealing that 
resistance might be due to steric hindrance presented by the Env’s V1/V2 loop with 
PGT121. To quantify the difference between the two V1/V2 loops, we selected the center 
amino acid in the V1/V2 sequence, Ser166, for both 4102-68 and 4102-3_6 and 




Ser54 on the heavy chain. The distance between 4102-3_6 and 3H+109L was only 3.088 
A° compared to 28.242 A° between 4102-68 and the same point on 3H+109L. This 
suggests that distance between the antibody and the envelope is influenced by the 
predicted orientation of the V1-V2 loop. 
The same prediction technique of overlapping Env structures on an 
experimentally solved antibody: virus complex was used to model the interactions 
between V3 directed bnAb, 10-1074, and 4012 HIV-1 Envs (Fig 4.5c). We used the 
crystal structure of a fully glycosylated BG505 SOSIP.664 (PDB ID 5T3Z) as a template 
for the interaction (Gristick et al., 2016). 4102-68 (AUC=0.839) and 4102-3_6 (AUC= 
0.499) were used again in this model because a difference in neutralization sensitivity 
was observed against 10-1074. We observed a similar interaction between subject 4102 
Envs in complex with 10-1074 as we did with the Envs in complex with the PGT121 
precursor. As before, the 4102-68 V1/V2 loop did not interact with the antibody, 
whereas, the 4102-3_6 V1/V2 loop interacted and possibly interfered with binding to the 
primary binding region. Again, the distance between the closest points between 4102-3_6 
Ser166 and 10-1074, Asp53 of the heavy chain, was calculated and compared to the 
distance between 4102-68 Ser166 and the same point on the antibody. The distance 
between 4102-3_6 Ser166 and 10-1074 Asp53 was 0.788 A°, compared to 15.433 A° 
between 4102-68 Ser166 and 10-1074 Asp53. This again suggested that V1/V2 loop 
orientation, as evidenced by the structural model and distance between two points, 




To validate this structural modeling data, we designed two sets of chimeric 
viruses in which the V1/V2 loop of a virus sensitive to PGT121 was swapped with a virus 
resistant to the bnAb, and vice versa (Fig 4.6a). Four co-circulating viral clones from 
subject 4102 (68, 61, 80, and 3_6) with different co-receptor usage and neutralization 
sensitivity to PGT121 were used as the template for the construction of the chimeric Env 
viruses (Fig 4.4a). Chimeric envs were tested for neutralization sensitivity to 5ug/ml of 
PGT121. Chimeras consisted of the start of the Env gene to the end of the V1/V2 gene 
(H) attached to the start of the C2 gene to the end of the Env gene (T). We found that 
when the V1/V2 loop of a virus originally sensitive to PGT121 (4102-68 and 4102-61) 
was replaced with a V1/V2 loop of a virus resistant to PGT121 (4102-3_6 and 4102-80), 
neutralization sensitivity to the bnAb was reduced (3_6H-68T and 80H-61T). Virus 
4102-61 was originally highly susceptible to neutralization by PGT121 (AUC=0.751, % 
Neutralization=96.8%). However, when the V1/V2 loop was replaced with a V1-V2 from 
a neutralization resistant strain 4102-80 (AUC=0.168, % Neutralization= 11.4%), the 
resulting chimera (80H-61T) had markedly reduced susceptibility (AUC= 0.195, % 
Neutralization= 18.4%) (Fig 4.6b). Similarly, introduction of a V1-V2 loop from a 
neutralization resistant variant, 4102-3_6 (AUC= 0.237, % Neutralization=30.9%), into a 
neutralization sensitive strain, 4102 -68 (AUC= 0.605, % Neutralization=93%) resulted 
in virus with markedly decreased susceptibility 0.241, % Neutralization= 34.2%) (Fig 
4.6b).  
The reverse chimeras demonstrated the importance of the V3 loop for PGT121 




V1/V2 loop of X4-tropic viruses, 4102-3_6 and 4102-80, that were resistant to 
PGT121were swapped with V1/V2 loops from neutralization sensitive strains, 4102-68 
and 4102-61, respectively, neutralization sensitivity was restored but did not reach the 
full level of neutralization observed for the original neutralization sensitive variants 
4102-68 and 4102-61. Neutralization only reached 44.6% (AUC= 0.300) and 58.8% 
(AUC=0.412) for chimeras 61H-80T and 68H-3_6T compared to 96.8% (AUC= 0.751) 
and 93% (AUC=0.605) for 4102-61 and 4102-3_6, respectively (Fig 4.6b). These results 

















Figure 4.3. Co-circulating X4-using viruses are less neutralization sensitive to V3 
loop bnAbs as compared to R5-using viruses.  
Neutralization sensitivity depicted as AUC (y-axis) for R5- (red) and X4- (blue) viruses 
for subject 4102 (circles) and 1233 (triangles) against (A) PGT121 and (B) 10-1074. 
Each point denotes a unique Env and is the mean from duplicate independent 


















Figure 4.4. Orientation of V1/V2 loop may dictate neutralization sensitivity to anti-
V3 loop antibodies. 
AA	position 119 158
V1/V2	loop 4102-3_6 C V T L N C T K I S N C S D V G N N A T N C T S E G K N N S R V I D A S E L K N L K N C S
4102-68 C V T L N C T K I S N C S D V G N N A T N C T S G G K N Y S R V I E T S E Q Q N L K N C S
4102-80 C V T L N C T K I S N C S D V G N N A T N C T S G G K N - S R V I D A S E L R N L K N C S
4102-61 C V T L N C T K I S N C S D V G N N A T N C T S G G K N K S R V I D A S E L K N L K N C S
AA	position 159 220
V1/V2	cont.	 4102-3_6 F N I T T N I P G R V Q K Q Y A L F D S L D V V P I N D E - N V N N S Y R L I H C N T S
4102-68 F N I T T N I Q G R V Q K Q Y A I F D S L D V V P I D D D K D N N N T Y R L I N C N T S
4102-80 F N I T T N I P G K V Q K Q Y A L F D S L D V V P I N D E - N V N N S Y R L T H C N T S
4102-61 F N I T T S I Q G R V Q K Q Y A L F D S L D V V P I D D D K D N N N T Y R L I N C N T S
AA	position 296 332
V3	loop 4102-3_6 N C T R L N N N K R K R I R I G H I G P G R T I Y A T E G I R G D I R Q A H C N
4102-68 N C T R L N N N T R K G I - - - H I G P G G A F Y A R G D I I G D I R Q A H C N
4102-80 N C T R L S N N K R K R I R I G H I G P G R T I Y A T E G I K G D I R Q A H C N




 (A) Alignment of V1/V2 and V3 loop sequences for 4102-68, 4102-3_6, 4102-61, and 
4102-80. (B, C) Models of (B) 3H+109L Fab, a precursor to PGT121, (purple) and (C) 
bnAb 10-1074 (pink) interaction with V3 loops of 4102-68(blue), R5 virus sensitive to 
PGT121, and 4102-3_6 (red), X4 virus resistant to PGT121, are shown. 4102-68 V1/V2 
loop (green) is predicted as facing away from both antibodies, while 4102-3_6 V1/V2 







Figure 4.5. PGT121 precursor, 3H+109L, superimposition with PGT121.  
PGT121 (pink) and 3H+109L (white) PDB files were stripped of all sequences except for 




















AUC % Neut. AUC % Neut. 
4102-68 R5 0.605 93.0 3_6H-68T R5 0.241 34.2 
4102-3_6 X4 0.237 30.9 68H-3_68T X4 0.412 58.8 
4102-61 R5 0.751 96.8 80H-61T R5 0.195 18.4 
4102-80 X4 0.168 11.4 61H-80T X4 0.300 44.6 
aNeutralization sensitivity of original virus to PGT121 
bNeutralization sensitivity of chimeric V1/V2 loop viruses to PGT121 
Figure 4.6. V1/V2 chimeras alter neutralization sensitivity of viruses to PGT121. 
(A) Schematic depicts chimera strategy to swap V1/V2 loops between viruses sensitive 
and resistant to PGT121. The portion from the start of the Env to the end of the V2 loop 
was labeled the head piece (H) and the reminder of the Env, the tail piece (T). (B) Table 
list PGT121 sensitivity to original 4102 viruses (4102-68, 80, 61, and 3_6) and V1/V2 




PGT121 tested (5 µg/mL) and well as AUC. All chimeric viruses were genotyped and 







In this study, we demonstrate that X4 viruses are less neutralization sensitive to 
V1/V2 and V3 loop directed bnAbs but not bnAbs against non-co-receptor binding 
regions. In a heterologous panel of viruses, we observed a significant difference in 
neutralization sensitivity to anti-V3 loop antibody, PGT121, and 2-fold differences in 
neutralization against 10-1074 and V1/V2 directed antibodies, PG9 and PG16. We did 
not observe neutralization differences to bnAbs that target other Env regions, such as the 
CD4 binding site and the MPER. Thus, neutralization susceptibility differences among 
CCR5- and CXCR4-using variants are specific for antibodies that target Env regions 
involved in co-receptor usage (Fig 4.2). A similar trend was observed among co-
circulating X4 and R5 viruses for subject 4102 (Fig 4.3). Importantly, isolation of co-
circulating variants allowed us to remove extensive Env variation, which made it possible 
to study the cause of neutralization differences observed between X4 and R5 viruses (Fig 
4.3). Using subject 4102 as a model, structural modeling predicted that the orientation of 
the V1/V2 loop of a virus resistant to PGT121 and 10-1074 faced towards the antibody 
and potentially interfered with binding. In contrast, a virus sensitive to both bnAbs had a 
V1/V2 loop that was oriented away from the antibodies (Fig 4.4). Finally, we confirmed 
our structural modeling predictions using chimeric V1/V2 loop viruses. We showed that 
V1-V2 along with the V3 loop influence susceptibility to V3 directed bnAbs (Fig 4.6). 
Chimeric envelopes with an exchanged V1/V2 loop that were not sensitive to the 
antibody drastically reduced neutralization sensitivity (Fig 4.6). In aggregate, our study 




recognize the co-receptor binding regions of Env and demonstrate that structural 
modeling can be used as a tool to understand mechanisms of resistance and predict 
neutralization sensitivity of anti-V3 loop bnAbs.  
IC50 has traditionally been used to quantify neutralization sensitivity. More 
recently, AUC has been used to fulfill the same purpose. Arguments have been made for 
the use of both quantification methods but not many studies have been done to correlate 
the two. Very few studies have investigated the correlation between AUC and IC50, with 
most of them performed in the field of cancer pharmacology (Brown et al., 2011; Jang et 
al., 2014). Very few HIV neutralization studies have examined the comparisons between 
the two quantification methods. Furthermore, these studies were performed before the 
discovery of bnAb and the standardization of the TZM-bl assay for analyzing 
neutralization susceptibility (Hioe et al., 2010; Yu et al., 2012). In this study, we 
examined multiple bnAbs using the now standard and well accepted TZM-bl assay. Our 
results show that both analysis methods present a viable and accurate way of presenting 
neutralization data. IC50 applies a strict cutoff to a data set, allowing only the analysis of 
neutralization assays that reach 50% inhibition. On the other hand, AUC incorporates all 
serial dilution data from a neutralization assay. IC50 only assesses differences around the 
50% inhibition point. AUC can show differences around specific inhibition percentages 
but can also highlight differences over the entire spectrum of dilutions (Yu et al., 2012). 
For the study of low levels of neutralization and/or antibody concentrations at a 





Prior studies assessing neutralization sensitivity to sera, plasma, and monoclonal 
antibodies have concluded that co-receptor usage does not affect neutralization sensitivity 
(Cecilia et al., 1998; Montefiori et al., 1998; Beaumont et al., 2000). As a result, the role 
of co-receptor usage has not been examined against bnAbs. Indeed, CXCR4-using 
viruses are not included in the global panel proposed as a standard neutralization assay to 
test antibody breadth and potency of potential bnAbs (deCamp et al., 2014). This study 
along with others, however, have now presented evidence that co-receptor usage does 
play a role in neutralization sensitivity (Pfeifer et al., 2014; Lin et al., 2016). Anti-V3 
directed bnAbs will potentially be introduced in the clinical arena in the future (Bhiman 
and Lynch, 2017; Caskey et al., 2017). Our results have implications for the potential use 
of this therapeutic modality. First, unlike common ARVs in clinical use, such as reverse 
transcriptase, protease and integrase inhibitors, there are no genotypic based algorithms 
that can predict resistance or decreased susceptibility to nAbs. Protein to protein docking 
modeling, similar to our work, could potentially be used to predict susceptibility of 
diverse Envs to different bnAbs. Second, resistance can develop when ARVs do not 
completely suppress virus replication. Although broad and potent nAbs have been 
isolated, in general, there are naturally occurring minimally susceptible or resistant 
variants against all bnAbs. In this setting, use of bnAbs directed towards Env regions 
associated with co-receptor usage may select for X4 variants over time. Finally, viruses’ 
resistant to traditional ARVs often have decreased replication capacity, and thus their 
emergence is not associated with worse disease outcome (Westby et al., 2007; Tsibris et 




CXCR4-using viruses in the presence of specific bnAbs would potentially lead to greater 
morbidity because co-receptor switching has been associated with faster disease 
progression (Koot et al., 1993; Richman and Bozzette, 1994; Connor et al., 1997). 
Although predicted CXCR4-using strains have emerged in mice treated with anti-V3 
directed bnAbs, similar variants were not reported in the one human trial that utilized 
anti-V3 directed bnAb, 10-1074 (Caskey et al., 2017). While in the human trial, escape 
often occurred with modification of the glycan at N332, more pathogenic resistant 
CXCR4-using viruses may also emerge following inoculation with multiple bnAbs rather 
than a single bnAb. This possibility will require further examination as bnAbs enter the 
clinical sphere.  
Currently, one of the only methods to assess neutralization sensitivity of a virus to 
an antibody is an expensive and time-consuming neutralization experiment (Todd et al., 
2012; Sarzotti-Kelsoe et al., 2014a; Sarzotti-Kelsoe et al., 2014b). This process involves 
cloning an HIV Env into a backbone or vector to generate a pseudovirus and testing 
neutralization suspectibility using a cell based system. These assays are not only time 
consuming, but, laborious. For use in the clinic, neutralization suspectibility to bnAbs 
will undoubtedly have to be tested prior to initation of treatment. Human trials 
demonstated that pre-treatment resistant mutations rendered bnAb therapy ineffective 
(Lynch et al., 2015; Caskey et al., 2017). Unlike ARVs, for which genotype or phenotype 
based assays are available, no such options are available for bnAbs that are rapid and 
cost-effective for clinical use (Arts and Hazuda, 2012). We have demonstrated that 




We have exploited the differences in predicted structure as the basis of a structural 
modeling based tool that can be used to estimate neutralization senstivity to antibodies. 
While our results focus exclusively on the V1/V2 loop, expanding this work into other 
regions of the HIV-1 Env is promising. Structural models of bnAbs that span the HIV-1 
Env are readily available in the RCSB Protein Data Bank, as are HIV-1 Envs from 
various subtypes, co-receptor usages, and in complex with various antibodies. Although 
additional studies are required to validate the selectivity and specificity of the proposed 
tool, our preliminary data suggest that it can be a viable option.  
In addition to being used as a prediction tool, structural modeling can be used to 
understand how viruses gain resistance. We used structural modeling to investigate 
changes in the Env that lead to bnAb resistance that were not readily evident by 
genotyping the Env. We observed neutralization differences between X4 and R5 viruses 
to multiple antibodies in the presence of intact epitopes. This is not a unique observation 
to our study. The recent phase 1 trials of 3BNC117 and 10-1074 found that resistance to 
each antibody occurred, as expected, however, was not always due to a mutation at the 
primary epitope (Caskey et al., 2015; Caskey et al., 2017). By using structural modeling, 
we can better understanding how viruses evade the humoral immune response.  
This study had one major limitation. Neutralization sensitivity to bnAbs were 
assessed on a relatively small sample size. Only 3 individuals with co-circulating X4 and 
R5 viruses were used to investigate neutralization differences in our inter-patient panel. 
Individuals who bear viruses that utilized the CXCR4 receptor proved to be rare. Of the 




with R5 viruses (chapter 3). From one of those subjects, 1924, we were only able to 
generate one X4 and one R5 virus, and therefore did not include it in our inter-patient 
analysis. Furthermore, 2 out of 3 of the subjects in the intra-subject pool were completely 
resistant to both anti-V1/V2 loop antibodies tested. This was rather unexpected because 
PG9 and PG16 have been shown to neutralize up to 52 and 57%, respectively, of viruses 
at less than 1 µg/ml (Euler et al., 2011). We tested neutralization sensitivity to at least 6 
times this antibody concentration. As a result of the observed resistance, we were unable 
to assess structural determinates of neutralization sensitivity to V1/V2 loop directed 
antibodies.  
In conclusion, we have shown that X4 tropic viruses are less neutralization 
sensitive to bnAbs directed against the co-receptor binding regions. In addition, we have 
identified a novel technique to predict neutralization sensitivity to bnAbs using structural 
modeling. In the midst of an increased interest and clinical trials of bnAbs as an HIV-1 
therapeutic, it is especially important to understand the relationship between co-receptor 
usage and bnAbs, and develop new tools for the fast and accurate investigation of 








CHAPTER FIVE: Concluding remarks 
Overview 
  Together, the chapters of this dissertation seek to understand the 
relationship between co-receptor usage and anti-HIV-1 Env antibodies. We used 
neutralization assays and structural modeling to understand the role selective pressure 
plays on the emergence of CXCR4 co-receptor usage. We identified specific HIV-1 
envelope genotypic, structural, and neutralization characteristics associated with CXCR4-
usage. In addition, we compared the humoral immune response between individuals with 
exclusive R5 viruses and DM individuals. Next, we used the same tools and subjects to 
examine the consequences of co-receptor usage on neutralization sensitivity to bnAbs. 
We found that co-receptor usage does influence neutralization susceptibility to antibodies 
that target regions which dictate co-receptor usage, such as the V1/V2 and V3 loops. We 
then showed that structural modeling can be used to predict neutralization sensitivity of a 
virus to anti-V3 loop antibodies.  
Summary of Major Findings  
In Chapter Three, we examined the role of selective pressure on the emergence of X4 
viruses and compared the breadth of the humoral immune response between individuals 
who bear exclusively R5 viruses throughout infection and DM individuals. The key 
findings are: 
• X4 viruses contain a 2-3 amino acid mutation in the V3 loop that is 100% of 




• Insertions in the V3 loop cause a second loop at the tip of the V3 crown that can 
cause steric hindrance with the CCR5 receptor and inhibit binding.  
• X4 viruses are less neutralization sensitive to heterologous and autologous plasma 
suggesting that X4 viruses are neutralization escape variants.  
• Individuals with DM virus population as compared to those that harbor only R5 
variants have similar neutralization breadth and potency against a global panel 
and DM panel of viruses; this argues that X4 viruses do not emerge as a result of 
a dysfunctional antibody response. 
  
In Chapter Four, we examined the role of co-receptor usage on neutralization sensitivity 
to broadly neutralizing antibodies using traditional neutralization experiments as well as 
structural modeling in a novel way. The key findings are: 
• X4 viruses are less neutralization sensitive to anti-V3 and anti-V1/V2 loop 
antibodies.  
• The orientation of V1/V2 loop of the HIV-1 Env can interfere with binding of V3 
loop directed antibodies.  
• Structural modeling can be used as a tool to predict neutralization sensitivity to 







The mechanism of emergence of CXCR4-using viruses has remained an area of 
contention since the discovery of HIV-1 co-receptors. Several hypotheses have been 
presented, and although none are mutually exclusive, none have fully explained the late 
emergence and persistence of X4 viruses during the late stage of HIV-1 infection (Regoes 
and Bonhoeffer, 2005) . However, it is possible that there are multiple mechanisms for 
the emergence of X4 viruses. In this scenario, emergence of X4 viruses will never fit the 
mold of one general hypothesis.  
In this work, I found neutralization susceptibility differences between X4 and R5 
viruses which suggest that X4 viruses are neutralization escape variants. Our hypothesis 
and conclusions of this work are in direct contradiction to previously reported studies 
investigating the relationship between antibodies/sera and co-receptor usage. Two studies 
in particular found that X4 and R5/X4 viruses were more neutralization sensitive to 
neutralizing antibodies and autologous serum compared to R5 viruses. One study 
investigated longitudinal samples from HIV-1 infected individuals against first 
generation bnAb antibodies while the second investigated virus from a SHIV infected 
macaque against serum and first generation bnAbs (Bunnik et al., 2007; Tasca et al., 
2008). The parameters of each study vary drastically and therefore, it is impossible to do 
a direct comparison of results of these studies. In particular, each study addressed a 
specific niche of virus. As will be discussed, X4 and CXCR4-using viruses appears in at 
least two varieties; viruses with substitutions and viruses with insertions in the V3 loop. It 




conclusions from these studies should not be generalized, however, the two previous 
studies have shaped the fields current understanding of co-receptor usage and 
neutralization sensitivity to bnAbs. This study specifically addresses the selective 
pressure that drives insertions in the V3 loop. As a result of these insertions, co-receptor 
usage is altered. It is clear that this pressure is highly specific. The observed insertions 
were well conserved between patient samples, occurring in only two distinct patterns in 
the only two regions of the V3 loop. These results argue that the mutation argument in 
the transmission/mutation hypothesis is unlikely (Regoes and Bonhoeffer, 2005). It can 
be reasoned that the location of the observed insertions is indicative of the selective 
pressure causing them. Both insertions coincided with a region of the V3 loop that has 
been found to be important for antibody binding (Cormier and Dragic, 2002; Mouquet et 
al., 2012; Garces et al., 2014; Caskey et al., 2017). Together with the neutralization data 
presented in this work, I propose the following model for the emergence of X4 viruses 
with insertions: R5 viruses are transmitted at the initiation of infection. A neutralizing 
antibody response is mounted against these viruses. Some individuals generate anti-V3 
loop antibodies that interact with residues within the V3 loop, in addition to N332 with a 
threshold potency. These anti-V3 loop antibodies put selective pressure on R5 viruses 
throughout the course of infection leading to neutralization escape in the form of 
insertions in the residue epitopes important for antibody binding, which in turn leads to 
X4 co-receptor usage late in infection. Individuals that do not generate a strong 
neutralizing antibody response against the V3 loop or generates antibodies that only 




emerge and therefore will not undergo co-receptor switching (Fig 5.1). It is also possible 
that anti-V3 loop antibodies drive neutralization escape and generation of X4 viruses with 
substitutions in the V3 loop, however, that was not investigated in this study and no 
conclusions can be made to that type of X4 variant.  
This work was done in the context of a specific type of X4 variant. All but one X4 
virus contained insertions in the V3 loop. This particular feature in the V3 loop is not 
found in all X4 viruses. In fact, the majority of the sequences in the Los Alamos database 
do not contain this insertion. Two possible interpretations can be made from this finding. 
The first is that our group has a biased method of only selecting X4 viruses with 
insertions. This conclusion is unlikely, however, because the same insertions were found 
in a separate study analyzing subtype C Envs by bulk PCR, with subtype C specific 
primers, and using pseudovirus production to test neutralization sensitivity to antibodies 
(Lin et al., 2016). In addition, reference strains HXB2 and NL4-3 share this insertion 
feature in the same location observed in our sequences. Together, the chances that the 
insertion are an artifact in our system or that some part of our system is biased towards 
these viruses is low. The second conclusion is that a majority of those Los Alamos 
database sequences, which do not contain the V3 loop insertion, are actually R5X4 and 
not exclusively X4 viruses. A variety of different methods are used to determine co-
receptor usage, with various levels of sensitivity (Coakley et al., 2005). Most recently, 
recombinant phenotypic assays have been developed and achieve high specificity to 
decipher between X4 and R5X4 viruses. Historically, however, co-receptor usage was 




distinguish between X4 and R5X4. Another common problematic method was the use of 
GHOST cells as target cells in reporter cell line assays. They express low levels of 
CXCR4 (Coakley et al., 2005). Sequences that populate the database phenotyped by these 
methods may be misclassified as X4 viruses in the database.  
 If multiple routes exist for co-receptor switching, the current scheme for the 
emergence of X4 viruses may not be all inclusive. It is generally believed that dual tropic 
viruses serve as the intermediary between an R5 and X4 viruses (Tasca et al., 2008). I 
propose that this study challenges that notion. Changes in the V3 loop at positions 11 and 
24/25 have been found to dictate co-receptor usage and the majority of studies 
investigating X4 virus emergence have been performed with or produced viruses with 
that specific genotypic profile (Cardozo et al., 2007). These changes are caused by single 
amino acid mutations and thus a substitution model can explain the multiple steps need to 
achieve an intermediary virus before an X4 virus emerges. Insertions, however, are not 
governed by the same model. No R5/X4 Env isolated in this study contained an insertion 
in the V3 loop. However, these Envs did obey the 11/24/25 rule, having at least one 
positively charged amino acid substitution at position 11 or 24/25 of the V3 loop. 
Selective pressure by neutralizing antibodies have been shown to cause insertions in V1 
and V4 in the absence of intermediary variants (Wu et al., 2012). It is, thus, reasonable to 
posit that insertions can occur by selective pressure on the V3 loop in the same fashion 
that these insertions arise in other regions of the Env. One study in a rhesus macaque did 




differed from the X4 variant insertion, HR, however, this has not been shown in humans 
(Tasca et al., 2008).  
 Anti-V3 loop antibodies may enter the clinical sphere as bnAb therapy. 
Antibodies 10-1074 and PGT121 are already under investigation (Caskey et al., 2017; 
clinicaltrials.gov, 2018). We found that X4 viruses are less neutralization sensitive to 
anti-V3 loop antibodies. This study suggest that introduction of these antibodies will 
drive neutralization escape and lead to X4 virus emergence. The current rate of X4 
emergence in HIV-1B is about 50%. This would suggest that 50% of HIV-1 individuals 
generate anti-V3 loop antibodies potent enough to drive neutralization escape. In the 
setting of V3 loop-directed antibodies as treatment, 100% percent of individuals on this 
therapy would be exposed to potent antibody repeatedly. A previous study from our lab 
demonstrated that pressure from autologous plasma was capable of selecting for CXCR4-
using variants (Lin et al., 2016). The virus that emerged did not contain the insertions 
found in this study which suggest that antibody pressure can cause both insertion and 
substitution in the V3 loop. Anti-V3 loop antibodies have not caused the emergence of 
X4 viruses in the clinical setting, however, length of time from treatment initiation to end 
of all bnAb clinical trials is only a few weeks to a couple of months at most (Caskey et 
al., 2015; Ledgerwood et al., 2015; Lynch et al., 2015; Scheid et al., 2016; Caskey et al., 
2017). In vivo, X4 viruses emerge only after years of infection at the chronic stage of 
disease. Anti-V3 loop humoral response develop as early as several months after 
seroconversion and bnAbs have been isolated from HIV-1 individuals as early as 20 




aggregate, low level persistent replication in the constant presence of V3 loop directed 
bnAb may eventually lead to the emergence of X4 variant with V3 loop insertions. Other 
BnAbs have the potential to revolutionize HIV-1 treatment, however. This work only 
implicates V3 loop directed bnAbs as being potentially harmful. 
 An interesting and unexpected finding of this work is the realization of structural 
modeling of the V1/V2 loop as a tool to understand and predict neutralization sensitivity 
to V3 loop-directed antibodies. The involvement of V1/V2 in dictating neutralization 
sensitivity is not novel, however. It has been reported since the early 1990’s that the 
V1/V2 loop can modulate neutralization sensitivity to neutralizing antibodies against the 
V3 loop and CD4 binding site domain (Koito et al., 1994; Morikita et al., 1997; Pinter et 
al., 2004; Sagar et al., 2006; Chaillon et al., 2011). Removal of the V1/V2 loop renders 
the Env more sensitive to neutralization (Cao et al., 1997; Stamatatos and Cheng-Mayer, 
1998; Johnson et al., 2002). In addition, structural comparison of the HIV-1 Env with and 
without the V1/V2 loop revealed that it overlays the HIV-1 core, acting as a shield (Hu et 
al., 2011). It is, therefore, a global regulator of neutralization and it may be possible to 
predict neutralization sensitivity to bnAbs against other regions of the Env, besides the 
V3 loop, by modeling the interaction between the Env and antibody in question. The 
structure of many bnAbs have been solved in complex with gp160/gp120. It is thus 
possible to expand and test the use of structural modeling to predict neutralization 
sensitivity to other regions of the Env. One other resource that will aid in the 
development of this tool is the Los Alamos HIV database CATNAP tool (Yoon et al., 




published IC50/IC80 for anti-HIV neutralizing antibodies. This tool will serve to generate 
both a test and validation panel for the tool without spending the time to produce the 
neutralization data needed. In summary, structural modeling is now possible because of 
all the tools that have recently been made available. With further studies, we hope to 
develop a rapid structural modeling based tool that would assess an Env for neutralization 
susceptibility to any given antibody.  
 
Figure 5.1. Model for emergence of CXCR4 viruses.  
Schematic represents the proposed model for emergence of X4 viruses with insertions in 
V3 loop. 
Future Directions 
This study suggests that X4 viruses are neutralization escape variants. Future 
isolation of antibodies from individuals with DM virus population would confirm that 
autologous neutralizing V3 loop directed antibodies provide selective pressure leading to 
escape. Our neutralization data using V3 loop directed antibodies against X4 viruses 
serves as preliminary data to substantiate our hypothesis and further investigation. In 
addition, we found that plasma from individuals with co-circulating X4 and R5 viruses 




these individuals may produce broadly neutralizing antibodies. Further exploration of the 
relationship between CXCR4 co-receptor usage and the production of bnAbs is 
warranted.  
The preliminary data presented in this work proposes structural modeling as a 
promising new avenue for the prediction of neutralization sensitivity of HIV-1 to bnAbs. 
This is the first study of its kind and would potentially have a great impact in the field as 
it is a fast and cost-effective way to predict neutralization sensitivity to bnAbs, in contrast 
to the standard neutralization assays currently in use. Additional studies are necessary to 
validate the sensitivity and selectivity of this potential tool. In this study, we focused 
exclusively on the co-receptor binding regions, V1/V2 and V3 loop, and the antibodies 
that target them. In future studies, we would like to expand on this work by developing 
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